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ABSTRACT
Non-invasive drug delivery systems for therapeutic drugs are gaining prominence. 
One such system, the nasal delivery system, shows good prospect for effective delivery 
of some drugs, however, it is yet to be well established for others. The preparation of a 
reformulated drug and studying its in vitro characteristics is a crucial step in the process 
of adapting the new drug for nasal delivery systems. The purpose of this research is to 
study the effect of electrostatic layer by layer assembly of polyelectrolytes on 
PROMAXX® insulin microparticles and to study the chemical, physical and 
corresponding release properties of the resulting formulations. PROMAXX® insulin 
microparticles of recombinant human insulin prepared and provided by Epic Therapeutics 
Inc®. During reformulation the temperature, pH, salt concentration and excepient 
concentrations were controlled to achieve maximum yield of final product and minimize 
raw material consumption. In vitro release studies were performed to study the release 
properties of various formulations prepared by electrostatic layer-by-layer assembly and 
compared with a standard insulin formulation. A key finding involved that the control 
release of insulin can be achieved by suitable selection of first polycation layer, and the 
consequent polyelectrolyte layers can be used to fine-tune the release. In addition, 
polyelectrolyte requirements were established for production of grams of final product.
iii
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To retard the permeability of thin films prepared with electrostatic layer-by-layer 
assembly, lipid bilayers were incorporated in layer by layer assembly. Study of diffusion 
properties of the composite multilayer films demonstrated that outermost lipid layer on 
hollow polyelectrolyte microcapsules acts as an effective diffusion barrier for FITC- 
dextran (MW 4300), which is comparable to insulin (MW 5800), and hence an important 
development towards imparting stealth and sustained release properties to low molecular 
weight drugs.
Hydrophobic drugs pose a problem for entrapment in polymeric matrices due to 
their poor solubility in aqueous media. In an effort to the study cores other than protein 
and drug microcrystals for nasal drug delivery, calcium carbonate microparticles 
incorporating phospholipids and hydrophobic molecules were prepared and 
characterized. The hydrophobic molecules were co-entrapped with anionic phospholipids 
in the calcium carbonate matrix with a near homogenous distribution of the molecules in 
the matrix, with loading up to 4 % (w/w) of calcium carbonate. Further, the anionic 
phospholipids influence the crystal morphology of calcium carbonate resulting in a 
decrease in release of hydrophobic molecules due to decreased rate of re-crystallization.
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CHAPTER 1
INTRODUCTION
Over the last ten decades healthcare has improved considerably throughout the 
world, improving life expectancy of humankind. Advances in science and technology 
have provided amenities for a comfortable living, which coupled with a sedentary 
lifestyle have led to an increasing number of people who suffer from diabetes. 
Pharmaceutical companies are trying to cope with increased demand for new drugs and 
better delivery systems for existing drugs.
Major players in the drug market are characterized by two main traits, namely the 
discovery of new drugs, or reformulation of existing drugs. The drug delivery market is 
intensely competitive and survival of a company depends on the ability to innovate and 
obtain patent protections for new developments and enhanced products. The cost of 
developing a new drug from discovery to marketing is close to a billion dollars. 
Therefore, emphasis on improvement of delivery methods is inevitable for the industry 
due to economic reasons. Lately, more attention is being given to particulate delivery 
systems with known size distributions to achieve better predictable pharmacodynamics 
and pharmacokinetics. An increasing number of patents are being filed for novel 
microencapsulation techniques themselves. This work is an effort to achieve that
1
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2competitive edge through product enhancement and innovation through the study of 
fundamental processes involving surface chemistry changes at nano and microscale.
1.1 Microencapsulation 
Microencapsulation is not a new concept and has been in use since the early 20th 
century. Numerous methods exist for encapsulation of many active agents, with wide- 
ranging applications including but not limited to food, consumer products, cosmetics, and 
pharmaceuticals. Microencapsulation in most instances aims to protect the encapsulated 
material and/or to enhance its stability. Many microencapsulation schemes involve the 
entrapment of simple molecules and usually entail harsh processing conditions such as 
high temperatures, and use of non-aqueous solvents and surfactants.
1.1.1 Microcapsules and Microparticles
A general summary of microencapsulation methods is presented in Table 1.1.
Table 1.1. Classification of microencapsulation methods [1].
Process Coating material Suspended medium
Interfacial polymerization Water-soluble and insoluble monomers Aqueous/organic solvent
Complex coacervation Water-soluble polyelectrolyte W ater
Coacervation Hydrophobic polymers Organic solvent
Thermal denaturatlon Proteins Organic
Salting-out Water-soluble polymer W ater
Solvent evaporation Hydrophilic or hydrophobic polymers Organic or water
Hot melt Hydrophilic or hydrophobic polymers Aqueous/organic solvent
Solvent removal Hydrophilic or hydrophobic polymers Organic solvents
Spray-drying Hydrophilic or hydrophobic polymers Air, nitrogen
P h ase  separation Hydrophilic or hydrophobic polymers Aqueous/organic
The microencapsulation methods described in Table 1.1 produce particles 
generally characterized as microcapsules or microspheres. Microcapsules can be defined 
as a continuous envelope enclosing a well defined core and microspheres as solid 
particles with a homogenous or a heterogeneous core. The alternate architectures of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3microcapsules and microsphere produced through the microencapsulation methods listed 
in Table 1.1 are shown in .
Gaseous core Sol k) com Liquid core
\v
V , /
Spherical
Irregular
; d j f i
Sphericat Irregular
Matrix Multi-
compartmental
\  /    \
Pure or dissolved Suspension
\ w /  VWv
Emulsion Emulston-
suspension
(a)
Gasacxis Solid Liquid
Spherical
Irregular
Spherical Soiid solution
Irregular
mm
Pure or dissolved Suspension 
drug
Emulsion Emutsion-
suspenskm
(b)
Figure 1.1. Various configurations of, (a) microcapsules and (b) microspheres [1].
Microcapsules consist of different solid, liquid or gaseous active material 
entrapped in a solid shell (a). Microspheres on the other hand have a solid matrix with 
active material dispersed as gas bubbles, liquid droplets, emulsions, or solid particles 
dispersed in the microsphere matrix. In this work two types of particles will be discussed
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4widely microcapsules of emulsion-suspension type with a semi-solid core such as insulin, 
and microspheres with solid solution type in which organic micelles occur discreetly in a 
solid calcium carbonate core ().
More recently, many new drugs coming in the market are large biomolecules such 
as proteins, peptides, DNA and oligonucleotides. The use of harsh treatment with such 
active agents could potentially result in degradation of the active agent, subsequently 
causing loss of bioactivity.
1.2 Importance of Size in 
Microencapsulation
A wide range of sizes is permissible for particle size in drug delivery depending 
on the drug delivery method employed and the nature of active formualation. Table 1.2 
summarizes the typical size ranges of pharmaceutically relavent particle sizes and their 
nomenclature.
Table 1.2. Particle dimension estimates in drug delivery [1].
Particle Size frm) Examples
0.001-0.5 Proteins, polymers, oligonucleotides, DNA, micelles, 
microemulsions, colloidal suspensions
0.5-10 Suspensions, fine emulsions, micronized drugs
10-50 C oarse emulsions, flocculated suspensions
50-150 Fine powders
150-1,000 C oarse powders
1,000-3,400 Granules
Currently, micronized drugs and microemulsions with narrow particle size ranges 
are becoming favored over larger particulate and/or polydisperse systems in both 
industrial and academic research. Small particles with a narrow size distribution have
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5more predictable release profiles and increased bioavailability. The micronized drug 
delivery with particles in the 0.5-10 pm range also show promise for nasal and pulmonary 
delivery of drugs [1].
1.3 Objectives and Novel Aspects
This work represents an advancement in a particulate drug delivery system with 
the emphasis on peptide delivery using layer-by-layer (LbL) electrostatic self-assembly 
and entrapment of hydrophobic molecules in an inorganic matrix. This work advances 
both particle-based drug delivery and the LbL technique itself. Further, it demonstrates 
for the first time the electrostatic LbL assembly of nanofilm coatings in the presence of 
high concentration of inert and semi-interacting polymer- poly(etheleneglycol).
This work demonstrates the use of economical but milder methods like the 
electrostatic LbL assembly, use of an aqueous medium, phospholipids, and biologically 
safer minerals such as calcium carbonate for preparing microparticles with reliably 
controlled particle size distribution.
This dissertation consists of two parts, the surface modification of insulin 
microparticles PROMAXX®, and the synthesis of calcium carbonate microparticles. 
Specific aims and the design of experiments to achieve the objectives will be thoroughly 
treated in the following discussion.
Hypothesis I
The assembly of LbL multilayers on insulin microparticles can be used to achieve 
a sustained release of drug from the microparticle, impart proteolytic resistance, achieve 
microparticle stabilization by preventing aggregation, stabilization of insulin tertiary
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6structure through complex formation with polyelectrolytes and achieve an outermost 
biocompatible coating to minimize immune response.
The work with insulin microparticles involved the surface modification of insulin 
microparticles, as achieved through the use of LbL assembly. LbL assembly was chosen 
because LbL assembly has significant advantages over other methods as it can be 
employed in an aqueous media to deposit nanometer-thick ultrathin films with a wide 
choice of materials. The conditions of LbL assembly can be achieved under mild 
conditions over a wide range of temperatures.
To achieve the objectives above, said a number of aspects related to LbL 
assembly need to be investigated. The first step involves choice of materials to perform 
LbL assembly, followed by determining suitable temperature, assembly buffers, pH of 
assembly, and centrifuge speed. Choice of materials was limited to biopolymers such as 
polyaminoacids, polysaccharides, polyamides, phospholipids, and naturally occurring 
peptides in either modified or unmodified form. However some experiments needed to be 
performed with synthetic polyelectrolytes to establish the feasibility, and to compare 
assembly results with biopolymers. This choice of biological polymers could offer better 
biocompatibility compared with synthetic polymers. To establish the assembly conditions 
and materials the first step involves the study and characterization of LbL assembly on 
flat substrates, and on microparticles. Such a study would enable the characterization of 
the effects of different material and concentration on the release of insulin microparticles.
A simple mathematical model accounting for the release properties of different 
polyelectrolyte layers, the number and order of layers would be impractical because of 
variable interactions of protein-polyelectrolyte complexes. Such interactions depend on
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the functional groups of polyelectrolyte with the functional groups on the insulin 
molecule, and the protein-polyelectrolyte complex can be reversible or irreversible. The 
temperature and pH of assembly and consequent release studies also affect the drug 
release from the microparticle. Therefore, analysis of experimental data has been used to 
optimize the LbL process, establishing various parameters required for scaleup.
In this work, to scaleup the process for production of grams of final product (pilot 
plant scale), the concentrations of polyelectrolytes, pH, temperature, centrifuge, assembly 
medium and number of process steps need to be established and standardized for unit 
weight of insulin microparticles. These parameters need to be established by 
experimentation. This physical and chemical characterization of microparticles prepared 
with different polyelectrolytes, at different assembly conditions, and the consequent 
release properties are expected to provide an insight into the most suitable 
polyelectrolytes for in vivo testing.
Controlled experimental conditions have been used in this work, and the 
experimental data generated have been used to optimize the final process scaleup, thus 
establishing concentrations o f polyelectrolytes and the resulting surface and release 
properties of the drug microparticles.
Hypothesis II
Phospholipid-polyelectrolyte composite films can effectively modulate diffusion 
properties of molecules smaller than MW 10,000.
As an advancement o f the work on insulin drug formulation, the use of 
phospholipids in combination with polyelectrolytes can effectively modulate the 
diffusion properties of LbL nanofilms.
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Such a scheme could minimize the number of process steps for nanofilms acting 
as a simple diffusion barrier [2], in addition to providing a biocompatible outermost 
coating. However, before it’s in insulin formulation, the optimization of suitable 
phospholipids compositions, and study of the multilayer-phospholipid-polyelectrolyte 
thin film properties is the fundamental step. Assembly of single phospholipid layer on 
polyelectrolyte multilayers has been demonstrated by Moya et al. [3]; however, 
multilayer polyelectrolyte/phospholipid assemblies have not been demonstrated. To study 
these properties, qualitative and quantitative techniques are required to establish 
phospholipids compositions and corresponding LbL film properties. In addition the 
optimized material composition and assembly conditions can be effectively used to 
design and test the diffusion properties of such thin films using a model compound 
similar to insulin. Thus, the refined technique could effectively be employed in 
modulating the diffusion properties of insulin.
The second objective is to develop a particulate drug delivery system stems from 
the need to develop suitable carriers for hydrophobic drugs. Most nasal delivery systems 
are based on polymeric microparticles, and face a major drawback due to poor systemic 
clearance of inert polymeric materials. Moreover, suitable dispersion mediums for 
polymer-based microparticles involve liquids, which consequently involve significant 
handling costs, and custom delivery devices. Mineral particulate systems for drug 
delivery are a recent development and well suited for delivery of drugs with existing 
nasal delivery devices. Calcium carbonate, apatite, and hydroxyapatite are three mineral 
particulate delivery systems gaining prominence because of their biocompatible nature. 
Among these calcium carbonate microparticles show promise due to their biodegradation
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9rates. Adsorption of drug on surface of microparticles and delivery in vivo has been 
shown to be effective for hydrophilic drugs. However, delivery of hydrophobic drugs 
using calcium carbonate needs to be developed.
Hypothesis III
Hydrophobic molecules can be entrapped in calcium carbonate matrix.
This work involves the development of one such system and establishes the proof 
of concept for entrapment of hydrophobic molecules in the calcium carbonate matrix. 
Calcium carbonate microparticles incorporating phospholipids in the matrix and 
consequently the co-entrapment of hydrophobic molecules are demonstrated. The 
characterization of the microparticles using various analytical techniques, such as 
thermogravimetric analysis, SEM and XRD is described. Establishing proof of concept 
for entrapment of hydrophobic molecules was achieved using a model hydrophobic 
fluorescent dye.
A system employing the use of phospholipids for entrapment of a species in 
calcium carbonate matrix is flexible and can in principle be employed to entrap not only 
hydrophobic drugs but also hydrophilic and peptide drugs. Large drug molecules such as 
proteins exhibit marked surface active property in that they partition or preferentially 
adsorb on surfaces at an interface; thus it is possible to entrap such molecules using the 
proposed scheme.
1.4 Organization of Chapters
This dissertation has been organized in chapters so that Chapters 3, 4, and 5 are 
self contained. Some degree of redundancy has been retained to make these chapters 
more readable as a contiguous piece work. Chapter 2 covers the background and theory
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of the material presented in Chapters 3, 4, and 5 as well as the principles behind the 
instrumentation and computation involved. Chapter 6 summarizes the entire work and 
provides recommendations for future work. Chapter 3 describes applicability of an 
established technique -  the electrostatic LbL assembly to enhance a pharmaceutical 
product PROMAXX®. Chapter 4 describes enhancement of the LbL technique by use of 
phospholipids. Chapter 5 describes the use of phospholipids to develop a novel technique 
to entrap small hydrophobic materials in an inorganic and relatively inert calcium 
carbonate matrix.
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CHAPTER 2
BACKGROUND AND THEORY
2.1 Introduction
In this chapter the literature concerning the insulin formulations, the LbL 
technique, and inorganic/organic matrices is reviewed with respect to drug delivery. 
Relevant instrumentation and theory used are presented to better understand the multiple 
but succinct references to the same in the following three chapters.
2.2 Market Outlook
Pharmaceutical companies market drugs based on less-than-perfect delivery 
systems or formulations, with their prime concern being limited to the safety and efficacy 
of the drug. Moreover, alternate development of drug delivery platforms and 
formulations is inhibited by patent protections. To overcome these drawbacks more and 
more pharmaceutical companies are partnering with drug delivery companies to co- 
develop marketable products. During the term of patent protection the parent company is 
guaranteed artificially inflated revenue for brand-name drugs, and patent expiration 
results in rapidly declining sales due to a host of generic drug manufacturers selling at a 
fraction of the price. Clinicians and patients may prefer reformulated brand-name drugs, 
possibly due to increased value or improved product, and the reformulation may in turn
11
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lead to patent extension. Patent expiry also creates a window for competing firms to 
improve drug formulations. Selecting a drug candidate for reformulation is governed by 
the market value it generates. Figure 2.1 shows the attractiveness of reformulation for a 
general drug[4].
Oral Tablet Capsule 1r u l i per day
Oral Tablet Capsule >1 
per day
Aerosol
Nasal
Transdermal
Injectable Release Depot
Hierarchy of 
Reformulation
Subcutaneous injection
Intramascular injection
IV injection
Figure 2.1. Hierarchy of reformulation [4].
2.3 Insulin Reformulations
2.3.1 Diabetes. Insulin and the 
Pharmaceutical Industry
Diabetes, a chronic metabolic disorder, continues to be a global epidemic,
affecting more than 170 million people (WHO) globally and increasing at an alarming
rate. Type I diabetes results from inability of the body to produce insulin. This form of
diabetes is treated with insulin injections. During the eventual course of type II diabetes
(due to insulin resistance) insulin injections need to be administered to control the
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progress of the disease [5]. Thus, currently the most viable form of treatment for diabetes 
for over four decades is injectable insulin. Insulin formulations, both slow-acting and 
fast-acting, are widely in use. Insulin formulations are usually injected subcutaneously, 
although more recently nasal, oral and transdermal delivery techniques are being 
developed. However, these variants have had limited success due to various problems 
such as dosage, bioavailability, and problems with prolonged use. Two popular injectable 
insulin formulations of insulin are Humulin®(Eli Lilly) and Glucophage®(Bristol-Myers 
Squibb) which generated a combined $1.5 billion in sales worldwide in 1997 alone and 
went off-patent in 2000 [6]. Many more drugs will go off-patent in 2005-2008, leading to 
a host of generic drug manufacturers fighting for a market share. Thus, market pressures 
for discovery of new drugs or reformulation of old drugs play an important role in 
determining the major players in the drug market [4].
Insulin was discovered in 1920s [7], and its method of administration has changed 
little since then. The purity and quality of the final product have, however, improved 
greatly with the advent of recombinant DNA technology. Control of blood glucose levels 
is the primary goal of insulin administration. Most commercial formulations achieve fast 
release ~30 min-2 hr to prolonged ~ 1 day of therapeutic levels of insulin. The fast-acting 
products/formulations target glucose levels immediately following a meal, and the long- 
acting formulation targets the basal glucose level. Depending on the individual, 
physicians prescribe a combination of both fast and slow formulations to achieve optimal 
glycemic control and minimize the number of injections required. Although techniques 
for delivering peptide drugs have evolved over the period of time the principal 
components of the formulation remain the same, namely zinc, protamine and insulin,
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which are commonly used in most formulations. Insulin is an attractive and widely
researched drug; numerous publications and patents exist on its formulations.
2.3.2 Phvsiochemical Properties of 
Insulin
Human insulin is a 51 amino acid peptide with molecular weight of 5700 and 
isoelectric point ranging from 5.3-5.4. However, the isoelectric point of insulin varies 
depending on conjugation, self-association, and modifications in amino acid sequence, or 
isoforms. Various sources suggest that the value of isoelectric point of insulin can be in 
the broad range from 5.2-5.9. The human insulin molecule consists of two peptide chains 
(A-21 amino acids and B-30 amino acids) linked by two disulfide bonds. The primary 
structure of human insulin is shown in Figure 2.2.
A-chain
cow
R-NH’
■NH-R
Figure 2.2. Primary structure of human insulin. The shaded regions 
are involved in self association [8].
The shaded regions show insulin self-association sites implicated in the formation 
of dimers or hexamers. Insulin usually assembles to dimers at acid and neutral pH; in the 
presence of zinc it forms hexamers [8]. It is slightly soluble in water and practically
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insoluble in alcohol, chloroform or ether. Because of its amphoteric nature it forms
soluble salts with weak acids and alkalis.
2.3.3 Design of Insulin Drug 
Reformulation
Proteins are macromolecules and differ from conventional small molecule drugs 
in that they are fragile systems with a complex architecture, and changes in the local 
environment of the protein can cause severe changes in the structure and function of the 
protein-drug, rendering it ineffective for treatment. The biological activity of the protein 
is retained only when the integrity of their structure is maintained. Administration of 
native protein alone does not achieve desired results because of rapid degradation 
processes that occur in biological systems due to proteolytic activity and rapid uptake and 
elimination. Therefore, it becomes imperative to design controls into the dosage form to 
achieve predictable and well-defined pharmacokinetics. Particulate delivery systems are 
more attractive to native enzyme because of enhanced protein and peptide stability, 
reduced protein degradation, increased chemical and biological stability, and increased 
bioavailability. The particulation of drugs can be achieved by spraying and drying 
techniques, use of solvent mixtures, and homogenizing [9]. During particulation, 
additives are added to the protein, and careful choice of materials reduces adverse effects 
[10, 11].
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2.3.4 Current Insulin Drug 
Reformulations
Insulin formulations and their variations can be broadly classified based on their 
solubility in vivo as fast-acting or slow-acting formulations. The excepients primarily act 
by conjugating/complexing with the insulin molecules in ways that enable either rapid 
release (phenolic compounds), or slow-release (protamine, zinc, pegylation), of insulin 
molecule from the complex. In addition to excepients, some formulations also regulate 
pH of formulation as a means to crystallize/solubulize insulin and thus achieving the 
desired release rate. Although different formulations contain variable concentrations of 
excepients, the general constituents of the formulations are summarized in Figure 2.3. 
Alternatively, insulin delivery platforms can be categorized by method of administration 
as
(a) Oral/Gastrointestinal.
(b) Nasal/Mucosal.
(c) Subcutaneous/Musculoskeletal.
(d) Transdermal and other intelligent drug delivery systems.
Each of these systems is discussed in greater detail, highlighting the current state 
of research and the most promising avenues.
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r~>  Improved solubility fast 
acting formulations
Phenolic compounds used as 
additives for fast release, delivery 
systems limited to Intravenous, 
Intramuscular, and Subcutaneous 
only. Helpful in emergencies
FORMULATIONS
Reduced Solubility Slow 
acting formulations
Others < -
More focus on this class of 
formulations to reduce patient 
inconvenience
^  Co-precipitation of insulin 
metal ion complexes
Zn2*, Cr2*, metal cofactors 
for insulin absorbtton
Complexation
Protamine sulfate, 
Heparin, Albumin
^  Recombinant DNA to 
modify of residues <
Alter isoelectric point 
towards pH 7.0 (reduced 
solubility occurs at 
isoelectric point)
Reduce proteolytic 
susceptibility and improve 
structural stability
Chemical conjugation PEG, Chitosan, Dextran based modificatbns
Encapsulation
f
Hydrogel based
PLGA, PEG, Alginate, 
Gelatin, Acrylamide
Latex, plastic and similar 
polymeric beads
Storage devices with 
controlled release
Acrylate, Cynoacrylate, 
Styrene Non implantable
Microneedle/ 
storage based
 1
Implantable
Controlled release 
depot/smart delivery 
platforms
Figure 2.3. Overview of Insulin Formulations.
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2.3.4.1 Oral delivery
From the reformulation hierarchy in Figure 2.1 it can be inferred the oral delivery 
of insulin is the most attractive. The first attempt to formulate insulin for oral delivery 
was by Oppenheim et al. [12] who prepared insulin formulation composed of particles in 
the ~200 nanometer range without polymers, where the insulin was cross-linked using 
glutaraldehyde. Damge et al. [13] loaded insulin into poly(alkyl cyanoacrylate) (PACA) 
nanocapsules by interfacial polymerization technique in which a mixture of insulin, 
isobutyl cyanoacrylate (IBCA), Mygliol® were added to an aqueous solution of 
poloxamer 188. This procedure resulted in interfacial anionic polymerization and 
formation of nanoparticles -220 nm in size. The encapsulation efficiency was 55% and 
the suspension was used without any further purification for in vivo tests. Michel et al. 
[14] also prepared poly(isobutyl cyanoacrylate) (PIBCA) nanospheres by the 
conventional emulsion polymerization technique [15]. The particles had a mean size of 
150 nm. The insulin microspheres lacked protection against proteolytic enzymes when 
suspended in water but were resistant to proteolytic action when dispersed in Mygliol®. 
Therefore, in the particles prepared with the emulsion polymerization technique, 
hydrophilic peptides tend to diffuse out to the surface of the particles which impedes the 
protection of the peptide.
Although partial adsorbtion in gastrointestinal tract was speculated for 
glutaraldehyde cross-linked insulin preparations, in vivo tests by Oppenheim et al. [12] 
were ineffective because glutaraldehyde denatures the insulin and causes loss of 
bioactivity. Moreover, the nanoparticles were predictably degraded by proteolytic 
enzymes of the gastric tract. Although, this formulation achieved a 15-20% reduction of
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glucose level in mice, which is nonetheless marginal for a commercially viable product. 
In the work of Damge et al. [13], a single 100 IU/Kg administration of insulin-loaded 
IBCA nanospheres resulted in reduction of glycemia by 65% in normal dogs with a 
glucose overload after 3 days of oral administration. Reduction reached 72% after nine 
days and 48% after 15 days. The glycemia returned to normal levels 21 days after 
administration. Damge et al. [13] claimed that this impressive prolonged effect was 
caused by altered biodistribution after oral administration of insulin-loaded nanoparticles. 
They also claimed that if sufficient number of intact nanocapsules were absorbed, 
nanocapsules would be localized in liver and spleen due to rapid phagocytosis. However, 
the purification and preservation of insulin-loaded IBCA nanocapsules poses a significant 
problem and is consequently poorly adapted for clinical use. To overcome this problem 
PIBCA based nanospheres were prepared by Michel et al. [14]. The PIBCA based 
formulation was effective after subcutaneous injection but induced no biological effect 
after oral administration.
The most promising work on oral delivery systems was done by Morishita et al. 
[16-18] who investigated pH-sensitive particles that would dissolve in various segments 
of digestive tract, in particular the jejunum or the ileum, where protease activities are 
lower. Morishita et al. incorporated insulin with or without protease inhibitor, which was 
dissolved in a small amount of HC1 (0.1 N). Ethanol and methacrylic acid copolymer 
(type A, Eudragit® L I00 soluble at pH >6, or type B, Eudragit® SI00 soluble at pH >7 
Rohm, Darmstadt, Germany) were added with stirring. This solution was emulsified into 
liquid paraffin, phase separated with gelatin solution (0.5% w/w), and the particles 
isolated. The isolated particles were coated with Eudragit® L I00 to avoid dissolution of
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the drug that was adsorbed on the surface of the particle. The total encapsulation 
efficiency of insulin was 78%. Good protection against pepsin was achieved; protection 
against trypsin and a-chemotrypsin was achieved with protease inhibitors. In vivo tests 
indicated that Eudragit® L microspheres had enhanced biological activity in fasting wistar 
rats (16-20 hr fasting).
The primary advantage of oral administration is the availability of the widest 
array of materials for formulation compared with all other routes of delivery; 
biocompatibility is limited to “edible substances”. The disadvantage of current 
approaches to oral delivery is the extremely high doses of insulin required, for even a low 
therapeutic effect compared with parenteral doses. Although the work looks promising in 
rodents and dogs, it is yet to be well tested in human subjects. Overall, the oral delivery 
formulations are still in the natal stages.
2.3.4.2 Nasal delivery
Evolution of new materials has stimulated interest in alternate drug delivery 
systems other than oral and injectable routes, and nasal drug delivery is an emerging 
field. Nasal dosage forms consist of preparations containing dispersed or dissolved drugs 
which can be either squeezed or sprayed into the nose, or applied topically as a gel 
(vitamin B i2) [19, 20]. The drugs target the nasal mucosa where they deposit and are 
absorbed. The nasal mucosa and epithelium primarily act as a lipophilic transport barrier, 
and transport across the membrane is related to the water partition coefficient [21]. 
Strategies to optimize the use o f mucoadhesives for nasal delivery of insulin include (a) 
preparing the formulations as micro- or nanospheres, (b) incorporation of absorption 
enhancers and (c) combination of different polymers [22], The formulation design should
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also consider factors such as pH, ionic strength, surface active agents, viscosity, and drug 
concentration [23], Enhancers are used in nasal formulations to improve drug absorption 
across the nasal membrane. The most evaluated compounds as enhancers are 
surfactants(laureth-9), bile salts (glyco-taurocholate, deoxycholate), chelators (EDTA, 
citric acid), fatty acid salts (oleic, caprylic, capric, and lauric), phospholipids (L-a- 
lysophosphatidylcholine (DDPC), didecanoyl-PC, fusidates (sodium 
taurodihydrofusidate, STDHF), glycyrrhetinic acid derivatives (carbenoxolone, 
glycyrrhizinate), cyclodextrins (a-, p-, y-cyclodextrins), hydroxypropyl-P-cyclodextrin 
and dimethyl-p-cyclodextrin (DMPCD), randomly methylated P-cyclodextrin (RAMEB), 
chitosan, and particulate carriers (microcrystalline cellulose, starch microspheres, and 
liposomes). Some of these compounds are also used in fast-acting formulations of insulin 
[9]-
Controlled studies in humans using phospholipid DDPC as an insulin enhancer 
have shown that nasal mucosal physiology was unaffected after intranasal administration, 
but that insulin bioavailability was low, despite intranasal doses about 20 times higher 
than subcutaneous doses [24]. Cyclodextrans are another class of compounds that show 
great promise in nasal drug delivery. They interact with polar/amphoteric molecules and 
also adsorb with specific lipids in biological membranes thus acting both as a carrier, and 
enhancer for hydrophobic drugs. In vivo studies by Merkus et al. [25] in rats have 
demonstrated that the addition of 5% a-CD to a nasal preparation of insulin resulted in an 
absolute bioavailability of approximately 30%; on the contrary, p- and y-CDs did not 
affect insulin absorption. However, DMPCD gave rise to a large increase in insulin 
absorption, with a bioavailability of 100%. Contrasting results were obtained in
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experiments with rabbits and human volunteers in which no absorption-enhancing effect 
of CDs for insulin was observed, with a bioavailability of approximately 3-5% [1, 25]. 
Thus, the effectiveness of CDs depends on both the drug and the animal being tested. 
Another prospective mucoadhesive formulation is chitosan, a positively charged high 
molecular weight polymer. For chitosan-based formulations Dyer et al. [22] showed that 
the most effective formulation for absorption is a chitosan powder delivery system, found 
to be better than chitosan nanoparticles and chitosan solution formulations, respectively. 
Callens and Remon reported that nasal administration of insulin formulated with drum- 
dried waxy maize starch (DDWM) or maltodextrins and Carbopol 974P, had the highest 
absolute bioavailability (14.4% for a mixture consisting of DDWM/Carbopol 974P 
90/10) [26]. However use of the formulation over a week in sheep showed reduced 
bioavailability due to high viscosity of the mucoadhesive formulation [27].
Thus, the bioavailability of the administered drug is a major problem in the nasal 
delivery of insulin formulation. However, development of pulmonary insulin delivery 
systems by commercial vendors is reaching critical and near market stages (Table 2.1).
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Table 2.1. Commercial development of pulmonary insulin systems [28].
Pulmonary Insulin Delivery Systems under D evelopm ent
D o s a g e  F orm T ra d e  N am e C o m p a n y D e v e lo p m e n t S ta g e
Solution AERx iDMS Novo Nordisk, Aradigm Phase III clinical trial in 
progress
A erodose A erogen Phase II clinical trial
com pleted;
dev e lo p m en t h a lted  in 
January 2003
Pow der Exubera Pfizer, Aventis, Nektar Phase III clinical trial 
com pleted ; long-term  
safety stud ies ongoing; 
m arketing  authorization  
application filed with 
European M edicine 
Evaluation Agency in 
March 2004; n ew  d rug  
application filed w ith FDA 
in 2005
ProMaxx Epic T herapeutics Predinical stud ies
AIR Eli Lilly, Alkermes Phase II clinical trial in 
progress
Spiros Eli Lilly, Dura 
Pharm aceuticals
D iscontinued after m erger 
b e tw een  Dura 
Pharm aceuticals an d  Elan 
Pharm aceuticals
T echnosphere MannKind Corporation Late Phase II clinical trial
Insulin System ongoing ; Phase III clinical 
trial in itia ted  in Europe
The bioavailability of commercial variants is in the range of 13-30%, slightly
higher than reported in research papers. Many enhancers used in the formulations for
nasal delivery are known to be biocompatible, and adverse reactions are limited
compared with intra-venous, intra-muscular, subcutaneous administration.
2.3.4.3 Subcutaneous/musculo­
skeletal injection
This is the most widely used and established form of insulin administration. 
Insulin formulations, depending on action, have common names and they have 
established pharmacokinetic characteristics. These formulations fall in one of the broad 
types based on duration of action as illustrated in Table 2.2.
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Table 2.2. Injectable insulin formulations [29].
PHARMACOKINETIC CHARACTERISTICS OF INSULIN 
FORMULATIONS (TIME IN HOURS)
Type of Insulin Onset Peak Duration
Slow-acting
Ultralente 3-5 10-16 18-24
Glargine 1-2 NA 24
Intermediate-acting
NPH 1-2 6-10 12-20
Lente 2-4 6-12 12-20
Short-acting
Regular 0.5-1 2-4 4-8
Lispro/aspart immediate 0.5-2 3-4
Most individuals are prescribed a combination of two or more types of insulin for 
optimal glycemia control. The pharmacokinetic profiles of individual insulin products 
however, differ significantly [30]. The ultralente insulin formulations are slow-acting and 
typically consist of zinc cross-linked hexameric insulin with or without protamine.
Insulin can be co-crystallized with zinc atoms to obtain numerous types of stable 
crystals with longer time actions than soluble or amorphous, uncrystallized insulin. The 
fish protein protamine has been used as insulin complexing agent to prolong the time 
action of insulin. Insulin glargine, insulin lispro, and insulin aspart are insulin analogues 
which have modified amino acids and hence complex with zinc and protamine 
differently. The NPH insulin is a protamine insulin complex and is intermediate acting. 
The fast-acting analogues are usually co-crystallized with zinc and phenolic molecules, 
and diffusion of the phenolic molecule away from site of injection causes the insulin-zinc 
crystal to break apart yielding monomers and hence the instantaneous action. Individual 
manufacturers add various stabilizing additives during the formulation including albumin,
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sugars, polyols, chelating agents and inorganic salts- to confer stability in solution, 
frozen and dried states as required.
Polymeric drug delivery has been studied for the past 30 years but few 
commercial products have come to market. It is gaining importance because of recent 
advances in polymeric materials and advantages offered by polymeric micro and 
nanoparticles for delivery of peptides. Polymeric materials are attractive for drug delivery 
because they afford protection to peptide drugs, prolong release, and have controllable 
biodegradeability. Commonly used materials for encapsulation of proteins are poly(l- 
lactic acid) (PLLA) and its copolymers with d-lactic acid or glycolic acid, which provide 
a wide range of degradation periods from weeks to years [31]. Most researchers use 
solvent evaporation or a modification thereof to prepare microparticles for controlled 
release [32, 33]. Emulsion, extrusion and spraying techniques can cause protein damage 
because they involve use of one or more of the following- organic solvents, elevated 
temperature, vigorous agitation and detergents. Controlled phase separation and use of 
aqueous biphase mixtures have also been employed to achieve micro- and nanoparticles.
Pfizer® in collaboration with Nektar® and Aventis® has developed a formulation 
based on pegylated insulin for nasal and possible IV delivery and recently launched their 
product Exubera™. However, it is not yet widely available.
Subcutaneous injection for diabetic treatment is currently the most effective 
control for both Type I diabetes and eventually Type II diabetes. For this method of 
administration, only FDA approved polymeric materials can be used in the formulation, 
which limits the formulation composition because few polymers have been approved for 
such use.
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2.3.4.4 Transdermal and other 
intelligent drug delivery 
systems
Minimally invasive insulin pumps are primarily used to treat the basal glycemia, 
and some are programmable to release drug at specified periods of time. Insulin is 
delivered transdermally using either a pressure activated, or an ionotropic, or an 
ultrasonically modulated device.
Pulsatile systems involving insulin in an ethylene-vinyl acetate copolymer 
(EVAc) matrix loaded with magnetic beads have been used to control the release of 
insulin in vivo in rats by application of an oscillating magnetic field. The release rate is 
dependent on the magnitude of the magnetic field and rigidity of the matrix. Similar 
results were observed with alginate-protein matrices [34-40].
An ultrasonically controlled polymeric delivery system in which release rates of 
substances can be repeatedly modulated at will, from a position external to the delivery 
system were tested by Kost et al.[41]. Both bioerodible and nonerodible polymers were 
used as drug carrier matrices. The bioerodible polymers evaluated were polyglycolide, 
polylactide, poly(bis(p-carboxyphenoxy) alkane anhydrides and their copolymers with 
sebacic acid. The releasing agents were p-nitroaniline, p-aminohippurate, bovine serum 
albumin, and insulin. Non-bioerodable system consisting of EVAc-insulin was also 
tested. In vitro and in vivo experiments in rats indicate feasibility of such a system. The 
release was modulated by the ultrasonic frequency, intensity and duration. Instantaneous 
release of encapsulated material over two minutes was achieved upon application of 
ultrasound [41]. Over 40 years, numerous clinical reports have been published 
concerning phonophoresis [42], This technique is based on the basic principle that the
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drug to be transdermally transferred is placed topically, followed by application of 
ultrasound. However, this method is not yet well established for protein drugs.
Competitive binding of glycosylated insulin to glucose and a saccharide binding 
protein such as Concavlin A as a release mechanism for regulated insulin delivery were 
first proposed by Brownlee and Cerami [43]. In vivo experiments in diabetic dogs show 
promising results.
Another such smart system involves a saccharide sensitive gel that swells in the 
presence of glucose. The gel consists of a covalently cross-linked polymer network of N- 
isopropylacrylamide in which the lectin and Con A are immobilized [44]. Other such 
smart systems involving intelligent glucose responsive chemistries have been 
demonstrated in vitro, but promising in vivo results are unavailable.
It would be fascinating and exciting to demonstrate the efficacy and long-term 
stability of smart chemistries in vivo. Fouling and lack of biocompatibility could be a 
potential problem in such systems after a prolonged period of time. However, smart 
systems currently available are underdeveloped for induction into the market. Glucose 
pumps are, to the best of my knowledge, the only commercially available devices for 
insulin delivery that have a minimally invasive approach. Popular vendors of glucose 
pumps include Animas Corp, Medtronic MiniMed Inc, Disetronic Medical Systems, Inc, 
and Deltec Cosmo.
Discussion: The nasal/aerosol-based delivery of insulin would be better than 
other methods of administration and this modality may become practically possible in the 
near future, considering current research levels in major firms. Time-release rates for the 
insulin formulations by themselves cannot be judged as good or bad because both short-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
28
and long-acting formulations may be necessary based on patient requirements. However, 
prolonged oral formulation of IBCA nanocapsules is most attractive in terms of control of 
basal glycemia because prolonged bioavailability of insulin for a single dose have not 
been achieved by systemic injection or other non-invasive methods.
The nasal/aerosol system has some drawbacks in its current form in terms of 
bioavailability of the drug after administration. However, it is theoretically possible to 
achieve quick-acting formulations because the rate of drug uptake in the lungs is 
exceeded only by intravenous injection. Oral delivery is nearly impractical for fast-acting 
formulations unless a very low molecular weight insulin analogue is discovered which is 
extremely resistant to proteolytic activity. Intravenous and subcutaneous drug delivery 
are painful, and patient compliance is not always good. It is particularly stressful for 
children.
Design Criteria for Coatings: As LbL-based insulin microparticles are primarily 
targeted for in vivo delivery, it is of paramount importance that all components must be 
completely biocompatible and produce no adverse reactions in diabetics. This project 
involves the development of long-acting insulin formulation, so it is important to have a 
tunable release of the drug with prolonged bioavailability. The outermost LbL layer 
should be designed to impart proteolytic resistance to the insulin microparticle. The 
coating should impart physical and chemical stability to the encapsulated insulin. Finally 
the procedure developed must be scalable and optimized with respect to concentrations of 
prospective polyelectrolytes to minimize the use of the same. Repeatability and 
consistency of product and method are essential for the final product.
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During the surface modification using LbL assembly, low temperatures should be 
maintained to prevent protein denaturation and/or complexation. Extremely low pH 
values (<4.0) should be avoided because they lead to increased solubility of 
PROMAXX® microparticles (insulin-zinc) that were used in this work. Phosphate salts 
and/or compounds containing phosphate groups should be avoided because phosphate 
moiety has a tendency to bind with zinc-complexed insulin, leading to reduced solubility 
and marked changes of pharmacokinetic activity of the final formulation. It is also 
important to avoid any other contaminants and non-sterile media in samples to be 
dissolution tested.
2.4 Phospholipids Retard Diffusion of 
LbL Thin Films
Electrostatic LbL has earned significant focus over the last decade because of the 
simplicity of the technique. It has evolved from the study of the fundamental science of 
LbL thin films to applications in real world product development. One practical area of 
interest is drug delivery. The basic scheme of the LbL assembly is shown in Figure 2.4. 
Thin films of opposite charge are deposited on a solid substrate by electrostatic assembly 
in an alternate manner to achieve sequential growth of thickness with each deposited 
layer. LbL assembly can be used to deposit thin films from a wide range of materials 
from metal complexes and polymers to proteins and nanoparticles (Figure 2.4 (top)), or to 
prepare hollow multilayer capsules (Figure 2.4 (bottom))[A5-Al],
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Figure 2.4. LbL schemes for polymers, proteins, nanoparticles 
(top). Preparation of hollow polyelectrolyte capsules (bottom).
The versatility of the process allows the use of LbL technique on both template 
particles and flat surfaces, irrespective of the size of the object. It can be used to design 
hollow capsules or thin films, and the choice of materials is extensive and limited by the 
charge on the polymer, nanoparticle or protein. Thorough reviews of the technique have 
been elaborated elsewhere [45, 48-52]. More recently, drug delivery applications were 
elaborated by the deposition of multilayer thin films on the drug microparticles [53-56],
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The primary focus of these works is the design of multilayer thin film coatings on drug 
crystals and the tuning of release properties by increasing the number of polyelectrolyte 
bilayers on the drug microcrystal. The universality of the idea implies no fundamental 
restriction on the choice of materials and the possibility of designing ultrathin ordered 
films in the range of 5-500 nm, with the precision of greater than one nanometer and a 
definitive knowledge of molecular composition.
The material selection for biomedical and pharmaceutical applications is large and 
expanding rapidly to include numerous biocompatible polyelectrolytes. Some of the more 
commonly used polyelectrolytes for LbL assembly are shown in Figure 2.5.
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Figure 2.5. Biocompatible polyelectrolytes in Layer-by-Layer assembly.
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Although the LbL technique is versatile and can be used in a wide array of 
schemes it is time consuming and laborious to deposit multilayer films. The method is 
not amenable to scaleup due to the large number of process steps involved. Therefore, 
there is a need for using materials that will modulate the desired property, such as 
diffusion, by an order of magnitude and to reduce number of process steps.
One prospective material in the field of drug delivery could be the use of 
phospholipids. Phospholipids have long been used in the pharmaceutical industry to 
deliver drugs in vivo. Moreover the diffusion properties of lipid bilayers for hydrophilic 
and water soluble molecules is low. Combining LbL assembly and liposome technology 
could yield benefits that will combine the advantages of both the technologies. The LbL 
technique enables the design of microccapsules of precise size, and liposomes could be 
used to tune the diffusion of these microcapsules. The concept is presented pictorially in 
Figure 2.6, where a charged solid core can first be coated with two bilayers of oppositely 
charged polyelectrolytes followed by alternate deposition of negatively charged 
phospholipids admixed with DPPC alternated with a positively charged polyelectrolyte. 
Such a scheme can be exploited to coat drug microparticles such as insulin to retard 
diffusion of drug from the core. To elaborate the scheme, a sacrificial core could be 
employed to produce a hollow polyelectrolyte capsule which can be used to permeate 
active drug followed by phospholipid/polyelectrolyte coating to entrap the drug for 
sustained delivery.
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on hollow polyelectrolyte
Figure 2.6. Schemes showing the alternate deposition of polyelectrolytes 
and phospholipids. Such architectures can impart special properties to LbL 
films like diffusion control and biocompatibility.
2.5 Caleiiim Salts for Delivery of 
Hydrophobic Drugs
Many anticancer drugs such as dexamethasone, paclitaxil, and some
chemotherapeutic drugs are hydrophobic in nature and thus have extremely poor
solubility in water. These drugs are typically administered by an intravenous injection of
a liposome-based formulation. Although new methods are being developed for delivery
of these drugs, such as the use o f pegylated amphiphilic molecules, these techniques
remain distant from the market and are still in preclinical trials. Effective administration
of these drugs eliciting low systemic toxicity could be possible through the use of a nasal
delivery platform with the use o f micro- and nanoparticles. Alternatively, nanoparticle-
based delivery mechanisms with slow biodegradability could be prospectively exploited
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if such drugs were entrapped in a mineral matrix of calcium carbonate. Such a system has 
been demonstrated in a rat model by Uneo et al. [57] for hydrophilic drugs and peptides.
Microparticles have been used for drug delivery for the last couple of decades. 
Most of the micro- and nanoparticles are organic[58] and some are inorganic [58, 59]. 
The use of calcium mineral salts incorporating drugs in the form of nano-microparticles 
of calcium carbonate (CaC03), calcium phosphate (Ca(H2P0 4 )2), tricalcium phosphate 
(Ca3(P04)2) and hydroxyapatite (Ca5(P0 4 )3 0 H), have been used in drug delivery [60, 61]. 
CaC03 has been reported useful as a carrier of hydrophilic drugs and insulin because of 
easy production and slow biodegradability [62-64]. In most of the work using calcium 
salt microparticles for drug delivery, the drug has been adsorbed on the surface of the 
micro- and nanoparticles. In a recent report Uneo et al. [57] have shown that both 
hydrophilic and peptide drugs can be incorporated into calcium carbonate nanoparticles. 
The authors further showed the feasibility of delivering the drug intravenously in rats 
without eliciting a systemic toxicity. Among all the minerals used for delivery of drugs in 
vivo, calcium carbonate has the highest lethal dose limit (-150 mg/kg body weight), 
making it one of the most promising candidates for drug delivery. It surpasses inert 
materials such as titanium dioxide, silica and apatite in terms of body tolerance. CaC03 is 
a food supplement and can be incorporated in the biochemical pathways, thus facilitating 
easy clearance from the body.
Most of the work relating to CaC03 has been in the area of study of its mineral 
polymorphs and crystallization mechanisms. Ozin et al. [65, 66] have studied in great 
detail the biomineralization scheme of calcium salts, particularly carbonate, apatite, and 
hydroxyapatite in association with biological materials such as amphiphiles, proteins, and
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polymers. Although incorporation and adsorption of hydrophilic drugs and peptides into 
the microparticles [53, 57] have been well studied and elaborated, the adsorption of 
hydrophobic drugs has not. Because most new drugs for the treatment of cancer are 
hydrophobic, design of effective and convenient drug delivery methods are important.
To study the physical and chemical changes at micro- and nanoscale requires 
appropriate instrumentation and suitable analysis of the results. The next section deals 
with the changes to standard measurement techniques and theory associated with it. The 
study of ultrathin films on flat surfaces needs characterization capable of measuring 
nanometer thickness changes such as quartz crystal microbalance QCM. Changes in 
colloidal particles coated with nanometer thick films can be characterized by studying the 
alternation of surface charge.
2.6 Instrumentation: Theory and Practice
2.6.1 Quartz Crystal Microbalance
QCM technique is capable of measuring thickness changes less than a nanometer, 
and mass changes less than a nanogram.
The following notation has been used for this subsection on the QCM.
Symbol definitions:
X - acoustic wavelength 
- speed of acoustic wave 
t - quartz thickness
F0 - resonance frequency of the quartz crystal
M  - Mass of quartz (between the electrodes)
A - area between the electrodes
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p  - density of quartz. 
p q - quartz shear modulus
Figure 2.7 is a schematic of the QCM, showing a transverse section of the quartz 
crystal with electrodes plated on the top and bottom of the crystal.
electrodes
Film deposition
X /2 = tq
X /2 ■ tq + tf
Figure 2.7. Transverse shear wave in a quartz crystal microbalance 
where tq is thickness of the quartz crystal, tf is the thickness of the 
film.
The piezoelectric effect of quartz is well known, when two electrodes are put at 
different potentials, an electric field results across the QCM, i.e., in the "y direction". 
Such an electric field in the "y direction" couples to shear motion "around" the z-axis, 
and vice versa. The end result is that shear waves in the quartz, in which the mechanical 
displacement is in the "x direction", also called the electric axis, are coupled to voltage 
between the electrodes. This phenomenon is used to study deposition of ultrathin films on 
quartz substrate.
In a quartz crystal which is cut along the A-T axis and coated with a fine layer of 
metal to act as electrode, a potential applied to the electrodes of a QCM produces an 
acoustic wave along the transverse direction, as depicted in Figure 2.7, of wavelength X.
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The Sauerbrey Equation can be derived as follows.
The wavelength is related to the thickness of the quartz can be represented by the 
following relation
xn = t (i)
Also,
* = r , / F a (2)
(3)
For a unit change in frequency,
AF  (4)
2t v 7
From equations M  = tA p , At -  AM /  A p , t = Vtr/2F^ and (1), (2) and (3) in Equation 
(4) we obtain
AF  -2 A M
—  =  (5)F0l V .Ap
This equation is called the Sauerbrey Equation
We can write Vtr = ■> where for quartz / i?=2.95xl011dyn/cm2 and p  = 2.65 g/cm3,
Z 'y
and Fo= 9x10 Hz and A -  0.16 cm for quartz crystals used in this work.
Substitution of these values into Equation (5) results in a working equation for 
measurement of the film thickness.
Discussion: The entire derivation above, and consequently the validity of 
Sauerbrey Equation, is based on the assumption that the material adsorbed on the quartz
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crystal is a rigid body (it vibrates/resonates in sync with the quartz crystal), so the change 
in frequency is directly correlated to the deposition of mass.
This derivation does not depend on the properties of the materials being adsorbed. 
For practical purposes, such as adsorption of polyelectrolytes and nanoparticles, these 
properties are unimportant because the mass of material adsorbed is < 1% of the mass of 
resonator itself. This mass is equivalent to ~200 nm thick film of polymers.
Biological materials however are not rigid bodies but behave as viscoelastic 
materials. Therefore, there is a delay from the time of application of shear to the onset of 
deformation, so the stress/strain relation is not linear. For such materials, the change in 
frequency is not proportional to the mass adsorbed. In typical situations the mass is 
overestimated due to frequency attenuation. Therefore, real time decay of the resonant 
frequency is used to estimate the changes in mass of the adsorbed material where 
deposition in aqueous mediums can be studied.
However, in this work QCM resonance frequency changes have been used to 
estimate thin film deposition with biological samples as well. To take into account the 
above constraints, it has been shown by Kankare [67] that for films with a thickness less 
than 45 nm, viscoelastic material such as proteins and hydrated polymers behave as a 
rigid body because in such circumstances the film consists <0.1% mass of the quartz 
crystal and the errors are not significant. Hence, for QCM studies of biological (soft) 
materials it is not advisable to go beyond this limit.
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2.6.2 Zeta-Potential and the Theory 
Involved
The equations, some statements and figures in this subsection have been reproduced from 
the book titled Paul C Hiemenz, Principles of Colloid and Surface Chemistry, 2nd Ed. 
Marcel Dekker, 1986. Discussion relevant to the current work is provided by the author.
A colloidal particle has surface charge attributed to it due to the presence of 
charged functional groups such as carboxylate, amine, hydroxyl, oxide, and others. Such 
groups cause discrepancy in surface charge of a colloidal particle or protein, and the net 
surface charge of the particle as a result of all the positive and negative charges on the 
surface is studied using zeta-potential.
The zeta-potential is a derived value and involves the combined effects of motion 
and electrical phenomena. Zeta-potential is therefore an electrokinetic phenomenon and 
is empirically equivalent to the double layer potential, and has a direct bearing on the 
colloid stability.
To begin the analysis of the formulas leading to zeta-potential and understand the 
limitations we have to begin from the Debye-Hiickel Approximation:
The variation of potential with distance from a charged surface of arbitary shape is 
described by the Poisson Equation
ay ay ay _ p
~T~Y + ~Z~r + T T  -  —  • (6 )ox oy oz s
Where,
¥  is the potential, p* is the charge density (coulomb/m3) and, s is the dielectric constant 
(eo sr) is product of permittivity of free space and permittivity of the medium.
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Equation (6) can be reduced to a one-dimensional form as for charge distribution 
from a planar surface
2^ * d y/ _ p
8x2 £
(7)
The charge density can be expressed in terms of potential with the Boltzmann factor as 
applied to ions.
n ,
n
= exp
f  z te y /^
i 0 V kT
(8)
where n; is the number of ions of type i per unit volume near the surface, and n,o is the 
bulk concentration, e is the charge of an electron, k is the Boltzmann constant, T  is the 
temperature in Kelvin and z,. is the valence of the ion and is either a positive or negative
integer. Thus charge density can be expressed as
p  = Z  zien>= E  zienio exp( ~ ^ (9)
Combining Equations (7) and (9) we have
d2y/
~dxr = exp
r -Z jey /^
kT (10)
This relationship is the starting point of Debye-Huckel theory of electrolyte non­
ideality, except that this relationship exists in a 3-D spherical coordinate system.This 
derivation implies that potentials associated with various charges are additive.
By expanding the exponential on the right hand side of Equation (10) into a power 
series and retaining only the first order terms of the equation, and by taking into account 
the electroneutrality, we have,
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( 11)
Integrating,
y/ = y/0 exp(-Kr) (12)
Where, k 2 - skT
A plot of —  versus distance from surface according to the Debye-Huckel
Approximation would show an exponential decrease in potential from the surface of the 
microparticle. This variation of potential results in attraction or repulsion of colloidal 
particles in solution, and the effective distance of interaction, in terms of molecular 
distance, is called the “double layer”.
Equation (12) can be written for a spherical particle as
In the Equation (13) the potential is rewritten as a function of charge. The Debye- 
Huckel Approximations are strictly applicable only for low potentials. These equations 
take into consideration the effect of electrolyte concentrations and valence of the charges, 
and are consistent with more elaborate calculations.
Throughout the preceding discussion charged particle was treated as a point 
charge without volume, but in practice they do occupy a volume and we define a “stem- 
layer” (Figure 2.8, stem surface) which occurs at a distance 8 from the actual surface and 
is drawn through ions which are assumed to be adsorbed on the charged wall. Applying 
this definition to a particle migrating in an electric field, a layer of fluid occurs on the
w -  ——  exp(- kt) 4 nar (13)
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particle surface that is immobilized and a surrounding layer on the particle occurs that 
moves at the same velocity as the particle due to surface shear (Figure 2.8). The exact 
distances of these layers are unknown but they are within a few molecular layers of the 
particle. It is however important to note that the surface of shear occurs well within the 
double layer.
Rather than identify the stem-surface we define the potential at the surface of 
shear to be zeta-potential represented by the Greek symbol A representation of these 
magnitudes of potentials is shown in Figure 2.8. Simplistically ^-potential is surface 
potential at surface of shear and the surface of shear is the effective particle dimension as 
measured by the instrument.
— r
Distance from 
Surface o f  shear surfaceStern surface
Figure 2.8. Relative magnitudes of potentials of interest.
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Distances within the double layer are considered large or small, depending on 
their magnitude relative to k"1. In dilute solutions, where k ' 1 is large, the surface of shear 
may be safely regarded as coinciding with the surface in units which are relative to 
double layer thickness. Therefore for small k  we can write Equation (13) as
£  = - * -e x p ( -* K )  (14)
AneR
where, R is the actual radius of the particle.
Expanding the exponential we have,
<7 1 q 1
AnsR exp(/rf?) AnsR (l + kR)
For small values of kR the above equation becomes
C = ~ ^ ~  (16)AnsR
Taking into account the motion of a spherical particle in an electric field (Stoke’s law to
account for the drag on the particle), the velocity of the charged particle can be
represented as
(17)
V
Also, the mobility is defined as velocity per unit field and u = — , where u is theE
electrophoretic mobility. Thus substitution of Equation (17) in (16) becomes
2 <
<18)
This equation is called the Hiickel Equation.
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This equation is valid for values where k R  less than 0.1, which means, that for 
particles of radius R=10'8 m the corresponding concentration is about 10 pM of a 
monovalent electrolyte. The product k R  is represented in Figure 2.9 pictorially as the 
Htickel limit, establishing a range of values for k  and R  .
This analysis assumes the particle to be a symmetrical rigid sphere with uniform 
surface charge distribution. Proteins or small protein complexes such as dimers hexamers 
are of the order of ~10 nm in size, rarely have a symmetrical charge distribution, and are 
not rigid bodies. Furthermore, changes in the local environment strongly influence the 
structure of the molecules/molecular complexes. The ^-potential is related to surface 
potential and but is not surface potential itself. It is merely a derived value which changes 
with the surface potential. Thus, the interpretation of ^-potential as an absolute surface 
potential should be used with caution.
When the double-layer thickness is much smaller than the particle itself, i.e. 
particles with large values of/d?, the solution of Poisson Equation and drag on the 
surface of the particle yield an equation similar to Equation (18), which is
This equation is called the Helmholtz-Smoluchowski Equation.
Unlike in Equation (18), Equation (19) requires no assumptions of the structure of 
the double layer. Only the Poisson Equation and bulk values of r| (viscosity) and e 
(dielectric constant) apply. This equation applies for k R  > 100 or for particles with sizes 
typically ~500nm and above. The exact applications of the above equations are depicted 
in Figure 2.9, as the theoretical boundries of colloidal science. However, practical 
experiments involving colloids involve particles with sizes up to 10 pm.
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Figure 2.9. The domain within which most investigations of 
aqueous colloidal systems lie in terms of particle radii and 1:1 
electrolyte concentration. The diagonal lines indicate the limits of 
the Hiickel and the Helmholtz-Smoluchowski Equations.
Equation (19) applies to whole cell ^-potentials and large protein aggregates. 
However, the Equations (18) and (19) are the lower and upper limits of the domain of 
colloids (Figure 2.9) which we study. Too-large particles would make suspensions, (they 
will settle over a period of time) and too-small particles will make solutions (like ionic 
moieties). Larger particles such as silica, melamine formaldehyde microparticles, 
polystyrene latex microparticles, and insulin microparticles, all have applicability near 
the upper limit where the Helmholtz-Smoluchowski Equation applies. On most occasions 
we study suspensions using the same relations.
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It may be argued that the absolute values of ^-potentials for biological samples 
obtained from the instrument are greatly inaccurate, first due to the assumptions involved 
in the theory and secondly due to the inaccuracies resulting from the solid theoretical 
background pertaining to such calculations. However, the ^-potential is used to study 
trends during LbL nanoassembly, and absolute values by themselves have little use. Thus 
under similar conditions we can safely assume the ^-potential to reflect the changes in 
surface potential of the microparticle in question.
Apart from surface charge characterization using ^-potential, colloidal particles 
with sizes over 1pm can be visualized using optical techniques such as confocal 
microscopy. Fluorescently tagged polymers or nanoparticles aid in visualizing particles 
that are not natively fluorescent.
2.6.3 Confocal Microscopy
Confocal microscope is an inverted compound microscope with laser optics, 
advanced electronics, and a software analysis system to study a sample under 
investigation. The primary advantage of confocal microscope is the laser light source. 
Unlike a regular microscope, chromatic aberrations are avoided by using a 
monochromatic light source from the laser; further, the effective resolution of the 
microscope is limited only by the wavelength of light used. Resolutions up to 190 nm can 
be achieved using a confocal microscope. The electronics and software included permit 
complex experiments like Fluorescence Recovery After Photobleaching (FRAP), which 
is illustrated in Figure 2.10 and has been employed in Chapter 4. The schematic of the 
model used is presented in Figure 2.10, which shows the bleach spot indicated by light 
grey color, and the region of interest indicated by the dark gray circle. The bleach spot is 
the area on the microscope slide where the laser intensity is maintained at maximum
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level. The region of interest is the area where we measure fluorescence recovery; note 
that this region is inside the capsule. The development of the diffusion model used in 
Chapter 4 is described here.
C apsule wall
Region of Interest w here 
fluorescence intensity is 
m easured  with time
_  ~10 nm thickness of 
— microcapsule shell
Laser bleach 
spot
Fluorescence 
intensity in the 
interior of the 
m icrocapsule 
averaged over a 
selected a rea  is 
m easured l(t), and 
normalized 
F(t)=l(t)/l(t<0)
Figure 2.10. FRAP experimental schematic for estimation of 
diffusion coefficient of microcapsules.
Development of a working diffusion model for hollow polyelectrolyte capsules is 
based on the model for Fluorescence Recovery After Photobleaching (FRAP) developed 
by Axelrod et al. [68], in two-dimensional coordinates, and the use of the model to 
calculate diffusion coefficient, elaborated by Blonk et al. [69] is presented later.
A two-dimensional model is chosen because the diffusion coefficient across a thin 
membrane (capsule wall in Figure 2.10) is of interest in the current work.
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The following assumptions are made for the model.
1. Diffusion of the species is effected primarily by the LbL assembly of the capsule.
2. In the lateral dimensions bulk diffusion is rapid and can be ignored for practical 
purposes, and the effective diffusion in the capsule interior is determined by the 
diffusion properties of the capsule walls.
3. Fluorescence intensity in the interior of the capsule (ROI Figure 2.10) at infinite 
time is equal to the fluorescence intensity prior to photobleaching
4. For the current situation, as the microcapsules are isolated on a glass slide covered 
with a cover slip, only lateral diffusion is important, and a two-dimensional model 
may be used.
5. The immobile fraction is assumed to be absent.
Based on the two-dimensional model proposed by Axelrod et al. [68], the normalized 
fluorescence recovery curve can be written as follows:
Where,
xD is the two-dimensional characteristic diffusion time and is related to the diffusion 
coefficient 
D by the relation
m -  = m < 0-
l + u 1 +
(19)
(20)
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and cd is the half-width of the Gaussian profile of the focused laser spot, it is usually 
determined at e~2 times the height of the profile. D (cm2/s) is defined by
k T
£> = - —  xlO4, (21)
6rjr
where, k  is Boltzmann’s constant, T  is the temperature (K), jj is the viscosity (N.s/m2) 
of the medium and r  is the effective radius (m) of the diffusing particles, k  is a bleach 
constant and depends on the sensitivity of the system for bleaching and is empirically 
related to the percentage of bleach by
% bleach = 10 0 * '~ 1 + g . (22)
K
The fluorescence recovery when an immobile fraction is present, due to irreversible 
adsorption, is given by
F(<) = F ( i ) { l - * ( l - /(» ) )} ,  (23)
where F(i) is the intensity of the bleach spot before bleaching, and R is the mobile 
fraction defined by
„ F ( o o ) - F ( 0 )
R = —— ----- — , (24)F(0-F(0) 1 >
where F(oo) is the normalized intensity of the bleached spot at infinite time after 
bleaching and F(0) is the normalized intensity just after bleaching.
However, for practical purposes the working model is designed as follows based 
on the schematic presented in Figure 2.10.
The value of co is determined experimentally to be 0.0000557, (Blonk et al.[69])
The bleach constant k  is calculated using the modified Equation (22) as
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where IQ is the fluorescence intensity of the bleach spot immediately after 
photobleaching, and I l<0 is the fluorescence intensity prior to photobleaching.
Normalized fluorescence intensity F (t) is obtained and the data is fitted to Equation (19) 
and td is estimated. Following which, an estimate for the diffusion coefficient is made 
using Equation (20).
2.6.4 Thermogravimetric Analysis
For a mixture of organic and inorganic samples or for inorganic samples 
containing thermally decomposable constituents, thermogravimetric analysis (TGA) 
provides a tool for quantitatively estimating the decomposable constituents. TGA relies 
on the principle of thermal decomposition of the material. The thermal decomposition or 
evaporation of solid products into gaseous form usually occurs at a temperature 
characteristic of that material. For example, during the decomposition of CaC0 3 , it 
breaks down into CaO and CO2 . However, organic material may be thermally 
decomposed into numerous products depending on the length of the carbon chain and 
other radical groups present. Pictorially, the working of the thermogravimetric 
measurement is shown in Figure 2.11, where a sample is heated at the rate of 5 °C/min 
and the resulting changes in mass are recorded.
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Figure 2.11. Principle of thermogravimetric analysis: a sample is 
heated at a fixed rate and mass changes are recorded with changes 
in temperature.
Thermogravimetric analysis can thus be used to estimate the thermal 
decomposition temperature o f different materials with the same or different 
stoichiometric composition. It allows the determination of strength of covalent and other 
linkages in the material.
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CHAPTER 3
SURFACE MODIFICATION OF INSULIN MICRO­
PARTICLES USING ELECTROSTATIC 
LAYER-BY-LAYER ASSEMBLY
3.1 Introduction
Due to the success of biotechnology development, proteins represent the fastest- 
growing segment of pharmaceutical products, but delivery of proteins in a controlled 
manner is a major challenge. Controlling the rate of release of the therapeutic agents from 
delivery devices offers prolonged therapeutic levels of the protein, improved 
pharmacokinetics and pharmaco-dynamics, and increased patient convenience and 
compliance. A variety of drug delivery approaches has been developed over the years to 
control release. Conventional methods include spray drying, spray freeze drying, milling, 
nondegradable and degradable polymeric systems, etc. The drawbacks of these methods 
are the use of organic solvents which are often incompatible with proteins, the 
complexity, and cost-ineffectiveness as discussed in great detail in the background 
material.
EPIC Therapeutics Inc. developed a simple, scaleable water-based process of 
microsphere formation via controlled phase separation of macromolecules with water 
soluble polymers that generates microspheres PROMAXX® with a narrow size
52
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distribution [70, 71]. The template PROMAXX® microparticle can consist of protein, 
peptide, nucleic acid, polymer, or low molecular weight compound. The aim of 
thecurrent research is to apply (LbL) assembly of oppositely charged polyelectrolytes on 
PROMAXX® insulin microspheres as a continuation of the particle formation process to 
obtain sustained release and control of surface functional properties.
The initial fundamental research on LbL assembly was performed on planar 
substrates. However, the LbL process is not limited to coating on large surfaces. The 
nanofilms may be deposited on tiny (micro- or nano-) three-dimensional templates [48, 
51, 72-74]. Functional nanocomposite films deposited on these colloidal carriers enhance 
biocatalytic reactions and allow controlled release of the encapsulated compound due to 
adjustable thickness of the capsule walls. The microparticles can be separated from 
polyelectrolytes after adsorption saturation, which is achieved via centrifugation or 
filtration. Latex, inorganic microparticles, and some drug microcrystals (1-5 pm 
Furosemide, Ibuprofen, Indomethacin, and Dexamethasone particles) have been 
nanocoated with linear polyelectrolytes with 5-12 polycation/poly anion bilayers, which 
gives capsule wall thicknesses of 20-100 nm [54, 56, 75-78]. Release time for these drugs 
was increased from ca 1 min for bare crystals to 1-3 hours for 8-10 bilayer encapsulation. 
10 pm insulin microcrystals also were encapsulated in 15 polylysine/sodium alginic acid 
multilayers, providing 10 times longer dissolution as compared with bare crystals. 
However, with less than 10 polyelectrolyte bilayers the release rates of bare and coated 
insulin microcrystals were similar [79, 80]. The nano-organized shell around drug 
microparticles was considered in these works as an adjustable diffusion barrier, and 
specific interaction with microcores was not considered. In another approach,
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interpolyelectrolyte complexation of drugs with polyelectrolytes to form microparticles 
spontaneously, was developed [81] but LbL assembly was not used.
In this work the combination of interpolyelectrolyte complex formation and 
organized multilayer shells are used to encapsulate 2 pm diameter PROMAXX insulin 
particles for controllable prolonged release. It was found that formation of 10-100 nm 
LbL multilayers on soft semi-soluble and permeable PROMAXX® insulin cores was 
insufficient to provide a significant physical barrier to slow the diffusion of insulin from 
the core into aqueous solution. Conditions for complexation of the outermost part of the 
insulin microparticles with the first polyelectrolyte layer were established, which played a 
critical role for sustained release, by decreasing the release rate of drug from the 
polyelectrolyte-complexed microparticle (Figure 3.1). Further polycation/polyanion 
multilayer assembly allowed fine adjustment of the insulin release profile (Figure 3.1). 
The odd polycation layers reinforced the microparticle complex, and even polyanion 
cores weakened the complex. The overall effect was a cumulative decrease in the release 
rate with increase in total number of odd polyelectrolyte layers.
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Figure 3.1. A schematic illustration of the assembly of polyelectrolyte layers on 
insulin PROMAXX® microspheres at pH 7.0.
3.2 Experimental Methods
3.2.1 Materials
Chondroitin sulfate C sodium salt (ChS, from shark cartilage), poly-l-glutamic 
acid sodium salt (PGlu, MW 17000), poly-l-aspartic acid sodium salt (PAsp, MW 
33400), poly-l-lysine hydrochloride (PLys, MW 22100), protamine sulfate (ProtS,) and 
poly-l-lysine hydrochloride fluorescein-labeled (PLys-FITC) were purchased from Sigma 
and used as received. Poly(sodium-4-styrene sulfonate) (PSS, MW 70000), 
carboxymethyl cellulose (CMC, MW 70000), poly(diallyldimethyl ammonium chloride) 
(PDDA, MW 200000), and polyallylamine hydrochloride (PAH, MW 70000) were 
purchased from Aldrich and used as received. Dextran sulfate sodium salt (DexS, MW
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500000) was purchased from Fluka, and poly-l-arginine hydrochloride (PArg, MW 
20000) from MP Biomedicals Inc.
PROMAXX® insulin microparticles (EPIC Therapeutics, Lot# 300X17) were
used as cores. The microparticles were fabricated using EPIC’s proprietary Controlled
Phase Separation (CPS) technology and the resulting suspension was frozen and stored at
-20°C until used. The LbL coating process was conducted in an aqueous solution
composed of 16% polyethylene glycol MW 3350 kD (PEG 3350) and 0.7 % NaCl unless
otherwise noted. The pH of this solution was adjusted to a desired value using either
hydrochloric acid or sodium hydroxide.
3.2.2 Layer-bv-Layer Coating of 
Insulin Microspheres with 
Multiple Polvelectrolyte 
Lavers
Before LbL coating, 20 mL aliquots of insulin microparticles were thawed at 
ambient temperature to melt previously frozen samples. The suspension of microparticles 
was then kept on ice (-2° C) during the entire procedure. Insulin microparticles with 
average diameter of 2 pm were separated from the supernatant by centrifugation at 2500 
rpm (Eppendorf 5804R), and the buffer was replaced with an equal volume of fresh 
buffer that was used for the set of experiments. The following buffers were used: (a) 16 
% PEG-0.7 % NaCl buffer with pH adjusted to a desirable value (5.8 or 7.0), (b) 16 % 
PEG-0.7 % NaCl, pH 7.0, containing 0.026 % ZnCl2 to reduce solubility of insulin, and 
(c) 0.16 % PEG, 1.3xl0'3 % acetic acid 0.026 % ZnCl2, pH 7.0 buffer.
For deposition of the first poly electrolyte layer, polyelectrolyte solution was 
added to insulin microparticles suspended in the 20 mL of buffer and thoroughly mixed. 
The final concentration of the polyelectrolyte in the supernatant solution was between
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0.005 and 1.5 mg/mL. After 60 min adsorption of the first polyelectrolyte layer, the 
microparticles were separated from the supernatant using centrifugation; the supernatant 
was removed and the microparticles were re-suspended in fresh buffer. The 
centrifugation / re-suspension cycle was repeated twice to remove traces of unadsorbed 
polyelectrolyte. The second polyelectrolyte layer with the charge opposite to that of the 
first polyelectrolyte layer was assembled by repeating the procedure above. Multiple 
layers of polyelectrolytes were adsorbed by repeating the procedure.
3.2.3 Quartz Crystal Microbalance 
Measurements
The quartz crystal microbalance (QCM) method was used to elaborate LbL 
assembly in the presence of PEG at different temperatures and estimate the thickness of 
the layers. A precursor film of (PAH/PSS)n films (n=2-4) was deposited on 9 MHz silver 
QCM resonators. Polyelectrolyte and protein layers were assembled from 1 mg/mL 
solutions of the substances in corresponding buffers. The time for deposition was 15 min 
or 1 hour per layer; the temperature was 2 °C (in melting ice). The QCM resonator was 
rinsed with DI water and dried in a stream of nitrogen after absorption of each layer. The 
frequency changes (AF) of the resonators was monitored using an universal counter 
(Agilent) with an attachment (USI-System, Japan) adapted for QCM resonators and 
translated into the thickness using the Sauerbrey Equation with the experimental scaling: 
At(nm) = -0.016AF (Hz) [52],
3.2.4 Microparticles Zeta- Potential 
Measurements
Zeta-potential measurements of microparticles were taken using a Brookhaven 
ZetaPlus microelectrophoretic system. For ^-potential measurements, 40 pL of the
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sample under investigation was added to 2.0 ml of buffer, mixed, and the suspension was 
analyzed immidiately. The temperature of the cell was equilibrated to 8 °C to avoid the 
dissolution of PROMAXX® insulin particles. In calculations of the ^-potentials using the 
Smoluchowski Equation, increased solvent viscosity due to the high (16 wt %) PEG 
concentration was taken into account.
3.2.5 Confocal Laser Scanning 
Microscopy
Confocal images of PROMAXX® insulin microspheres were taken with a 
confocal laser scanning microscopy (Leica DMI RE2) equipped with 63x oil objective. 
Fluorescent labeling of ProtS and PLys with FITC were performed with the standard 
procedure [82, 83].
3.2.6 In Vitro Release Study
Dissolution of insulin microspheres was studied by addition of 10 ml of the 
release buffer (10 mM Tris, 0.05% Brij 35, 0.9% NaCl, pH 7.4) into glass vials 
containing 3 mg equivalence of the insulin microspheres, and incubation at 37°C. At 
designated time intervals 400 pL of the medium was transferred into a microfuge tube 
and centrifuged for 2 min at 13000 rpm, and 300 pL of the resulting supernatant was 
removed and stored at -80°C until analyzed. The 300 pL of fresh medium was added to 
the remaining portion of the collected sample, the pallet was reconstituted, and was 
transferred back to the corresponding in vitro release medium. The amount the released 
protein was estimated with the bicinchoninic acid (BCA) assay.
To determine protein content, a known amount of microspheres was suspended in
1.0 ml 0.01 N HC1. The medium was centrifuged at 13000 rpm for 5 minutes at 4°C. The
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protein content in the supernatant was determined by BCA assay, using solutions of 
insulin in 0.01 N HC1 to construct the calibration curve.
3.3 Results and Discussion
3.3.1 Electrostatic LbL Assembly 
in the Presence of PEG
In earlier works on LbL assembly, experiments to determine the feasibility of 
LbL assembly of polyelectrolytes in the presence of high concentrations of other 
hydrophilic macromolecules had not been performed [47,48, 74].
Therefore, first it had to be determined whether polyelectrolytes and proteins 
could be assembled in aqueous solutions containing up to 16 % PEG, which is necessary 
for insulin microparticles’ stabilization. Figure 3.2(a) shows a linear step-by-step increase 
of film thicknesses for different poly electrolyte films assembled in 16 % PEG-0.7 % 
NaCl, pH 5.8 and at room temperature. Stable growth of the films is observed for 
different polyelectrolyte combinations. The assembly of polyelectrolytes in the presence 
of PEG resulted in thicker films, compared with LbL films obtained in DI water without 
any polymer additives, and had a typical bilayer thickness of ca. 2-11 nm (Table 3.1).
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Figure 3.2. Quartz crystal microbalance data for assembly of 
different polyelectrolytes from 1 mg/mL solutions in 16 % PEG- 
0.7 % NaCl buffer, pH 5.8 at room temperature (a) and over ice 
(b). Experimental errors are ±0.5 nm.
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Table 3.1. Bilayer thickness (in nm) for polycation / polyanion assemblies in 
16% PEG-0.7% NaCl, pH 5.8, room temperature, 15 min per layer.
Polyanions Polycations
PLys PArg ProtS
DexS 4.9±1.0 4.2±0.8 5.0±1.5
ChS 6.3±2.0 11.3±3.9 5.4±1.4
Alginic acid 6.7±2.2 6.7±2.3 1.8±0.4
PEG is well known as a complexing and aggregating agent, which induces bulk 
coil conformation in polypeptide and DNA molecules [84]. Therefore, the presence of 
PEG can increase polyelectrolyte layer thickness.
Therefore it can be concluded that electrostatic LbL assembly of polyelectrolytes
and proteins can be carried out in the presence of hydrophilic uncharged polymers. In
related work, a competitive adsorption of polyelectrolytes from binary mixtures was
recently reported [85, 86].
3.3.2 Influence of Temperature on 
LbL Assembly in the 
Presence of PEG
To prevent undesirable dissolution of the microparticles, the LbL assembly was 
performed in the temperature range of a low 2-5 °C. The influence of low temperature on 
polyelectrolyte assembly in the presence of PEG was investigated for DexS and PLys 
combination using QCM. At 2° C, the assembly still occurs, but the bilayer thickness 
after 15 min deposition is much lower than that for the same combination at room 
temperature (0.6 nm vs 4.9 nm). The thickness of a polyelectrolyte bilayer was restored 
by increasing the adsorption time to one hour to achieve a thickness of 2.2 nm for a 
DexS/PLys bilayer. Similar results were obtained for other polycation / polyanion pairs.
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All QCM resonators were initially coated with several PSS/PAH bilayers to create 
a uniformly charged surface and to mimic the surface of the microparticles under 
investigation (Figure 3.2(b)). The bilayer thickness for the films assembled in 16 % PEG- 
0.7 % NaCl buffer, pH 5.8 is between 1 and 5 nm depending on composition (Table 3.2).
Table 3.2. Bilayer thickness (in nm) for polycation / polyanion assemblies 
inl6% PEG-0.7% NaCl, pH 5.8, 2 °C, 60 min per layer.
Polyanions
Polycations
PLys PArg ProtS Gelatin B Chitosan
DexS 2.3±0.3 1.8+1.2 1.110.2 4.811.1 3.210.2
ChS 1.4±0.3 3.2±0.4 1.5±0.2 1.810.4 2.710.5
PAsp 1.3±0.1 5.1±0.5 1.310.2
PGlu 4.310.7 3.710.5 1.010.1
It can be assumed that intermediate rinsing with DI water done after adsorption of 
each layer removes most o f the hydrophilic PEG, making the final structure of the films 
close to that obtained in the absence of PEG. At the same time, as can be seen from Table
3.1 and Table 3.2, the experimental errors observed for different combinations are 10-15 
%. This variation can be associated with trace amounts of PEG varying from layer to 
layer in the films due to minute differences in film rinsing.
In some of the QCM experimental series, to simulate conditions closer to 
deposition on insulin microcores, an insulin layer was additionally deposited on the top of 
the PAH/PSS precursor to simulate conditions closer to the assembly on insulin cores 
(Figure 3.2(b), seventh assembly step). The thickness of the insulin layer was 4.5 ±1.0 
nm, which corresponds to adsorption of ~2 monolayers of insulin. As insulin is positive 
at pH 5.8, the insulin layer was followed by a polyanion layer. A slight decrease in film
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thickness was observed for all films as the insulin layer was partially removed.
Polyanions peel off some loosely attached insulin molecules and adsorb on the top of the
films, since it was observed that the film thickness increases again with assembly of the
next polycation layer. This behavior is common in protein/polyelectrolyte LbL assembly
[52], To conclude this section, the conditions desirable for coating of insulin microcores
were determined as 2 °C and 60 min per layer deposition and are used hereafter.
3.3.3 Coating PROMAXX®
Insulin-Microspheres with 
Polvelectrolvtes
Figure 3.3 shows the surface charge reversal of insulin microparticles after 
adsorption of single layers o f different polyelectrolytes at 2 °C. Further, the results for 
assembly are described 1) at pH 5.8, below isoelectric point of insulin where 
PROMAXX®-microcores are positive, and 2) at pH 7, above its isoelectric point 
(apparent pi = 5.9) where PROMAX® insulin microparticles are negative.
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Figure 3.3. Surface charge of microparticles after deposition of 
different bilayers at pH 5.8 (a); and pH 7.0 (b).
3.3.3.1 pH 5.8. positive core
At pH 5.8, insulin microparticles are positively charged and negative 
polyelectrolytes as PSS, PAA, ChS, DexS, Alginic acid, PGlu, PAsp were chosen to be
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adsorbed as the first layer. After polyanion adsorption, the surface charge of 
microparticles changes to a negative value, indicating a successful deposition. Then a 
polycation, for example PLys, was adsorbed as the second layer and the surface charge of 
the microparticles reversed. Insulin microparticles coated with different polyanions as the 
first layer and PLys as the second layer show varying magnitudes of positive charge. This 
variability could result from the interaction of PLys with the polyanion layer, which 
affects the amount of adsorbed PLys, its structure, and ionization.
3.3.3.2 pH 7.0, negative core
Figure 3.3(b) presents the results of coating insulin microparticles at pH 7.0, 
above the isoelectric point of insulin. At this pH, the microparticles were negative, and 
polycations were used as the first layer. After polycation adsorption, the charge of 
microparticles changes to a positive value (left side, Figure 3.3 (b)), indicating successful 
adsorption onto the microparticle surface. In the following step, a polyanion can be 
adsorbed as the next layer (right side, Figure 3.3(b)).
By alternating positively and negatively charged polyelectrolytes, a multiple 
coating consisting of 3-5 polyelectrolyte layers was formed on PROMAXX® insulin 
microspheres. Figure 3.4 shows monitoring of surface potential for some shell 
compositions that are potentially interesting for encapsulated PROMAXX® particles.
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More than one pair of polycation and polyanion can be used to coat a 
microparticle, providing a complex shell composition. Such a complex architecture
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increases the number of variants in designing shells with different properties and provides 
better control over microparticles’ dissolution profile. Formation of multilayered coatings 
on the microparticles is complicated by insulin dissolution, which slowly occurs, even at 
low temperature. The amount of insulin remaining in the samples decreases after 
deposition of each layer. More than 50 % loss of insulin was found for a sample after 
completing the deposition procedure corresponding to 3-4 polyelectrolyte layers 
corresponding to 6-8 hrs of processing time. This loss makes assembly of the capsules 
with more than two polyelectrolyte bilayers undesirable because of low yield of the final 
product.
3.3.4 Optimization of the 
N anoencapsulation 
Conditions
The dependence of ^ -potential on total concentration of polyelectrolyte in the bulk 
is shown in Figure 3.5. With the 20 ml aliquots of insulin-microparticles in PEG buffer as 
basis, and a working volume of 20 ml in the PEG buffer, the concentration of the 
polyelectrolyte forming the outermost layer was varied in the range of 0-1.5 mg/ml. The 
plot with closed diamonds represents the ^-potential with a single layer of ProtS. The 
other plots represent the effect ChS (open circle) and CMC (closed triangle) in Figure 
3.5, after a ProtS layer. ProtS as a third layer (closed square) is adsorbed after sequential 
assembly of ProtS and CMC.
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7.0 on insulin microparticles in solutions with different 
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that were coated with ProtS at 1.5mg/ml. Closed squares represent 
particles that were first coated with ProtS at 1.5mg/ml, followed by 
CMC at 1.5mg/ml and finally a second layer of ProtS.
3.3.4.1 pH 7.0. negative core
A complete charge reversal for cationic ProtS adsorption on negative microcores 
(Figure 3.5) is observed only for solutions with concentrations higher than 0.3 mg/mL. 
Lower concentrations of ProtS are not sufficient for recharging of the microparticles’ 
surface. This observation is different from those made previously for LbL assembly in 
aqueous solutions in the absence of PEG, where a polyelectrolyte concentration as low as 
0.001 mg/mL was enough to form a saturated polyelectrolyte layer [45, 47]. A similar 
dependence was found for adsorption of the second polyanion layer (Figure 3.5).
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3.3.4.2 pH 5.8, positive core
The concentration needed for complete charge reversal in the case of anionic
CMC and ChS is also elevated. For CMC, the minimal concentration level is around 0.1
mg/mL and for ChS it is 0.3 mg/mL.
In both cases, the degree of ionization of polymer functional groups and the
charge density on the polymer chains determine the polyelectrolyte concentration needed.
Competition between adsorption of PEG and polyelectrolytes could probably explain the
increased concentration of polyelectrolytes needed for the LbL assembly in 16 % PEG as
compared with aqueous solutions. Besides, it may indicate that the amount of insulin
interacting with polyelectrolytes is not limited by the protein molecules located on the
surface. Taking into account the properties of microparticles, permeation of
polyelectrolytes into the microparticle interior and formation of complexes deeper within
insulin microsphere matrix can be expected. The permeation of polyelectrolytes into the
microparticles could increase the polyelectrolyte concentration needed to cause charge
reversal of the microparticles.
3.3.5 Polvelectrolvte Interaction with 
Microparticles
3.3.5.1 At pH 7.0
The interaction of polyelectrolytes with microparticles can be visualized using 
confocal microscopy using fluorescently labeled polyelectrolytes. Figure 3.6 (a) shows a 
confocal fluorescence image of insulin microparticles covered with one layer of FITC- 
labeled ProtS at pH 7.0 when core particles are negative. One can see that FITC-ProtS 
fluorescence emanating from a ring around the microparticle. The interior of 
microparticles is also partially fluorescent and the fluorescence intensity profile (Figure
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3.6 (a)) shows that intensity of interior is of about 20 % of that of the walls indicating that 
some amount of ProtS-FITC forms complex with the insulin in the core matrix.
Figure 3.6. Confocal images of insulin microparticles coated with, 
a) FITC-ProtS layer in 16 % PEG-0.7 % NaCl, pH 7.0; and (b) 
PSS/FITC-PLys at pH 5.8.
3.3.5.2 At pH 5.8
At this pH microparticles are positive, and negative PSS was used as the first
layer, followed by FITC-labeled polycation, PLys. Again, narrow fluorescence rings
occur around the microparticles in the confocal microscopy image (Figure 3.6 b). We
conclude that the fluorescently labeled polyelectrolyte is attached to the microparticle
surface, but some fluorescence in the microparticle interior was also observed.
3.3.6 Modification of Microparticle 
Solubility
Unmodified insulin microparticles dissolve rapidly in a physiological solution. A 
large shift of pH from 5.8 (pH of the insulin suspension) to 7.4 (dissolution pH) with
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simultaneous increase in temperature from 2 to 37°C makes the dissolution of insulin 
virtually instant. Therefore, we studied encapsulation at lower pH 5.8 and at higher pH 
7.0.
3.3.6.1 pH 5.8, positive core
This pH is close to the apparent isoelectric point of insulin in the 16% PEG, 0.7% 
NaCl buffer. Polyanions were adsorbed as the first capsule layer. In spite of alternation of 
surface charge at these conditions, dissolution tests did not show significant reduction in 
release rate with the deposition of different assemblies of charged polyelectrolytes 
(Figure 3.7).
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Figure 3.7. Cumulative in vitro release of insulin from 
microparticles coated with CMC and ProtS up to two bilayers at 
pH 5.8 .The control is uncoated microparticles suspended in PEG 
buffer at pH 5.8.
Microparticles coated with a single layer of polyanion show solubility similar to 
that of an unmodified sample. At the same time, the next polycation layer decreases the
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amount of insulin released to -60 %. At this pH the solubility of insulin microparticles 
coated with a polycation layer as the outermost layer is somewhat lower than that of 
microparticles with a negative outermost layer, but this dependence is not pronounced.
3.3.6.2 pH 7.0 negative core
At this pH, insulin microparticles are negative and different polycations were used 
to form the first layer (Figure 3.8).
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Figure 3.8. Cumulative in vitro release of insulin from 
microparticles coated with single layer of polycation at pH 7.0.
The control is uncoated insulin microparticles.
For such modified microparticles the initial release is still rapid. Insulin 
concentration in solution reaches saturation after 30 min. However, in many cases, the 
release level is much lower than 1 0 0 %, which implies that most of the insulin is fixed 
inside the microparticles due to complex formation with polyelectrolytes. It is known that 
a single polyelectrolyte layer does not form a diffusion barrier on the surface [48, 74].
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Polycations with charged flexible side chains, such as PAH, PArg, and PLys, slow down 
the release to a larger degree than PDDA or chitosan having the charged groups on the 
main polymer chain. The action of ProtS can be attributed to its chemical structure, 
which, predominantly consists of Arg and Lys residues. A polyanion layer deposited on 
top of the polycation changes solubility of microparticles, increasing it up to 80-100% 
(Figure 3.9).
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Figure 3.9. Cumulative in vitro release of insulin from 
microparticles coated with ProtS as the first layer and subsequent 
layers of polyanions- PAsp and CMC at pH 7.0. The control 
represents uncoated microparticles.
The effect of different polyanions is not as pronounced as the action of the first 
polycation layer. If a polycation is adsorbed as a third layer, the solubility of the 
microparticles decreases again. Coating of insulin cores at pH 7.0 (when the core is 
negative) with a polycation fixes the insulin in the core; addition of a polyanion relaxes
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the structure and allows for complete release. The third layer of polycation again 
strengthens the shell-core complex. The QCM studies demonstrated that there are no 
specific features of polycation/polyanion multilayers assembled on a solid support. 
Therefore, formation of interpolyelectrolyte, and insulin-polyelectrolyte complexes in the 
microcore are responsible for such release profile. The dissolution properties of 
microparticles follow the same trend for all investigated polyelectrolyte combinations 
investigated.
• • • .Insulin microparticles can be coated by LbL in the buffers containing Zn ions,
which have an important influence on the synthesis and action of insulin in body [87]. 
Zinc decreases general solubility of insulin but does not change the general influence of 
polyelectrolytes on microparticle dissolution. At pH 7.0, the effect of polycation and 
polyanion layers deposited on the microparticle surface on dissolution of microparticles 
is similar to that in obtained without Zn2+ ions.
Therefore, the dissolution properties of insulin microparticles can be controlled by 
alternating polyelectrolyte layers on microparticles’ surface. If coating pH and 
dissolution pH are on the same side of the isoelectric point (e.g., test pH 7.4 and coating 
pH 7.0 for insulin with pi 5.9), a polymer with opposite charge (a polycation above 
isoelectric point and a polyanion below it) decreases dissolution of the microparticles due 
to formation of electrostatically bound inter-polyelectrolyte complex between these 
macromolecules. The second polyelectrolyte layer competes with insulin for the 
previously adsorbed polyelectrolyte and thus weakens its interaction with the protein. The 
concept of a diffusion barrier formed by polyelectrolyte multilayers is less applicable for 
thin coatings consisting of 3-4 polyelectrolyte layers.
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3.3.7 Effect of Polvion
Concentration on Release of 
Insulin from Microparticles
It has been shown that surface properties of microparticles can be changed by
varying polyelectrolyte concentration in coating solutions. The influence of concentration
on microparticle dissolution is shown in Figure 3.10.
-♦-ProtS -A-ProtS/ChS -OProtS/CMC -B-ProtS/CMC/ProtS
Figure 3.10. Concentration dependence of outermost
polyelectrolyte layer on insulin release in vitro after 48 hours from 
insulin microparticles coated with different polyelectrolyte 
concentrations in 16 % PEG-0.7 % NaCl pH 7.0.
For a single ProtS layer, the dissolution level reaches a plateau at around 0.3 
mg/mL. The relationship between dissolution and concentration parallels the relation ship 
between ^-potential and concentration in Figure 3.5. As soon as the polyelectrolyte 
concentration is enough for complete charge reversal of microparticles’ surface, the 
dissolution of the microparticles reaches a saturation level and depends only slightly on
20
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further increase in concentration. A similar situation is observed for the second layer. For 
CMC or ChS at a concentration lower than 0.3 mg/mL, percent release is proportional to 
the amount of polyelectrolyte in the supernatant and almost reaches a maximum at 0.5 
mg/mL. The deposition of the third layer, ProtS from a 1.5 mg/mL solution, brings the 
degree of dissolution back to a minimum. Varying supernatant concentrations during 
adsorption process helps to control insulin release from the microparticles.
The yield of the final product relative to the initial amount of protein used is an 
important parameter in developing sustained release drug formulations. The total insulin 
amount in the samples decreases with addition of new polyelectrolyte layers due to the 
losses during coating. Most of the losses occur when the samples are coated with a 
polyanion layer. Therefore, to avoid the waste of insulin from PROMAXX® 
microparticles, the conditions favoring low dissolution must be employed during LbL 
assembly. At pH 7.0, elevated polycation concentrations and lower polyanion 
concentrations are optimal.
3.4 Conclusions
Nanoorganized encapsulation of protein microcores in the presence of high 
concentration of neutral polymers (PEG) was elaborated with LbL assembly. Uncoated 
insulin PROMAXX® microparticles formed by controlled phase separation from 
hydrophilic compounds dissolve rapidly if  PEG concentration is decreased. LbL 
encapsulation extended insulin release time from PROMAX®. After the first layer of 
oppositely charged polymer is formed over the insulin core, the microparticle is stabilized 
and new polyelectrolyte layers can be added. Balancing strong interaction of the first 
polyelectrolyte layer with the protein microcore, and easing this interaction by depositing
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the second oppositely charge polyelectrolyte (polyanion/polycation for positive cores at 
pH 5.8, and polycation/polyanion for negative cores at pH 7.0) allowed us to control 
complexation of the encapsulated proteins and to achieve a sustained release of insulin. 
The release profile was fine tuned by adding the third and fourth polyelectrolyte layer.
Therefore, the general idea of the controllable complex formation is as follows: 
adsorption of the first polyelectrolyte layer results in strong complex formation and slow- 
release. An addition of the second, oppositely charged polyelectrolyte layer, results in 
relaxed complex and quicker release. The third oppositely charged layer again gives 
slower release, and so on. Simple increase in thickness of the capsule walls in the range 
of 5-10 bilayers (30-60 nm) does not slow insulin release from the microparticles. With 
this, we converted the concept formulated in a Max Planck Institute’s research group [48, 
72, 73, 75, 76] where a LbL multilayer was considered as a tight diffusion barrier with 
adjustable thickness in the range of 5-12 bilayers, to the new approach where the main 
role in the controlled release from protein micro aggregates is the adjustable 
interpolyelectrolyte complex formation controlled by alternate polycation / polyanion 
coating of 2-3 monolayers.
In this chapter it was shown that a polyelectrolyte-complex on the outermost 
protein layer of the drug microparticle controls of release properties of the drug. In the 
next chapter we will see an alternate method for control of diffusion of small hydrophilic 
molecules from hollow polyelectrolyte microcapsules.
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CHAPTER 4
LAYER-BY-LAYER ASSEMBLY USING PHOSPHOLIPIDS 
AS A DIFFUSION BARRIER
4.1 Introduction
Conventional liposomal drug delivery is a well established method for in vivo 
delivery of pharmaceutical compounds with focus on injectable delivery forms. However, 
choice of materials for liposomal shells is limited. One way to create precise control with 
liposomal delivery methods would be to use phospholipids with the LbL technique to 
blend the biocompatibility of liposomal delivery with the versatility of LbL technique for 
making thin films and hollow shells. LbL assembly of amphiphilic molecules and 
polyelectrolytes can yield biomimetic systems for various applications[48, 8 8 , 89]. The 
assembly of lipid bilayer membranes alternated with polyelectrolytes has been 
demonstrated on solid supports [3, 90, 91]. The polyelectrolyte/lipid architecture formed 
as microcapsules can have some advantages over liposomes due to better structural 
support and control over size of microcapsules [3, 91].
A lipid membrane onto solid or polymer-precoated templates can be created by 
direct vesicle fusion [3, 92-95] and the Langmuir-Blodgett technique [90, 92-96]. In both 
cases electrostatic forces play an important role in film formation. By vesicles (liposome)
78
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adsorption, a uniform lipid bilayer forms rapidly, within 5 min after addition of solution 
to substrate, and covers more than 95% of the surface [92-96]. The almost perfect bilayer 
coverage was shown on negatively charged silica for neutral zwitterionic lipids and their 
mixtures with low concentration of negatively charged lipids. A uniform bilayer was also 
shown for lipid on mica and polyethylenimine-supported surfaces [92-96]. In some cases 
adsorption of more then one lipid bilayer on polycation coated surfaces was deduced 
from the thickness of the obtained films [3,91].
Here, we report results of direct coating of polyelectrolyte microcapsules with 
lipid layers of different composition, and the first quantification of its influence on 
capsule permeability using the fluorescence recovery after photobleaching (FRAP) 
technique. The polyelectrolyte/lipid microcapsules, with controlable permeability, is of 
interest for drug delivery applications.
4.2 Experimental
4.2.1 Materials
The lipids— l,2-dipalmitoyl-s«-glycero-3-phosphatidylcholine (DPPC), 1,2- 
dipalmitoyl-sM-glycero-3-phosphate (DPPA), L-a-phosphatidylglycerol (PG), L-a- 
phosphatidylcholine (PC) were purchased from Avanti Polar Lipids, polyethyleneimine 
(PEI MW 30,000), polyallylamine hydrochloride (PAH, MW 70,000), poly(dimethyl 
diallylamide hydrochloride) (PDDA, MW 100-200,000), polystyrenesulfonate (PSS MW 
70,000), fluorescein isothiocynate(FITC) labeled Dextran (FD, MW 4000) and 
chloroform were purchased from Sigma and chitosan was obtained from Wako Fine 
Chemicals Japan. Polymethacrylate (PMA, 3 pm) were obtained from Fluka, manganese
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carbonate microparticles were synthesized in the lab with the procedure elaborated by 
Shchukin et al. [77].
4.2.2 Preparation of Unilamellar 
Liposomes
Unilameller vesicles of DPPC containing 5, 10, 17, 20 % (w/w) of DPP A and 
those of PC with 10, 20% (w/w) of PG were prepared by mixing the reagents in 
chloroform followed by solvent evaporation. The lipid cake was hydrated using 
Deionized (DI) water to obtain a concentration of 1 mg/mL solution of liposomes in DI 
water, and the mixture was subjected to ultrasonication, followed by extruding the 
liposomes using a 0 . 2  pm nylon filter to obtain unilamellar liposomes.
4.2.3 Preparation of Polvelectrolvte 
Solutions
PEI, PAH, PDDA, and PSS were prepared as a 2 mg/mL solution in DI water at 
pH 6.5 and used without further purification. Chitosan is sparingly soluble at normal pH, 
so it was dissolved in 0.1 N HC1, and the pH of the solution was adjusted to pH 6.5 with 
concentrated NaOH prior to use.
4.2.4 Assembly on Quartz Crystal 
Microbalance
Negatively charged lipid layers were deposited from 1 mg/mL suspensions in 
alternation with PEI, PAH, PDDA, and chitosan on silver QCM resonators [46], The 
resonators were coated with three PAH/PSS bilayers as precursor layers. Frequency 
change of the resonators was measured only after deposition of polyelectrolyte layers to 
prevent rearrangement of lipid bilayers due to drying.
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4.2.5 LbL Assembly on PMA 
Microparticles for C-Potential 
Studies
For each set of polymers 10 pi PMA microparticles were taken in a 
microcentrifuge tube and 1 mL of 2 mg/mL polyelectrolyte or 1 mg/mL of phospholipid 
solution was added and the particles were allowed to stand for 15 minutes to complete the 
adsorption step. Following the adsorption step, the microparticles were centrifuged at 
4000 rpm for 10 minutes and the supernatant discarded to remove excess of material in 
solution. The pellet was resuspended in 2 mL DI water and the procedure repeated three 
times in all to remove excess polyelectrolyte/ lipid in the solution phase. After, rinsing 
the particles three times, surface charge (^-potential) measurements were taken to check 
for alternation of surface charge.
4.2.6 Phospholipid Coatings on 
Hollow PAH/PSS 
Microcapsules and 
Measurement of Diffusion 
Coefficient of the Capsule 
Wall
For capsule preparation, 0.2 mL of 3 mg/mL PAH and PSS solutions in 0.5 M 
NaCl at pH 6.5 was added alternately to 15 mL of a suspension containing 25 mg of 
MnCC>3 cores with a mean diameter of 5.5 ±0.3 nm (SEM microscopy). After 15 min 
adsorption of each layer, the particles were rinsed with deionized water three times. The 
cores were dissolved with 0.1 M HC1. The traces of Mn2+ were removed by washing with 
a 0.1 M ethylenediaminetetraacetic acid solution and deionized water. The empty 
capsules, after dissolution of the inner cores, can be slightly swollen or shrunken 
depending on the media they are in and the presence of other substances.
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The operation sequence proposed by Moya et al. [3, 91] was employed to coat 
capsules with a lipid bilayer for FRAP experiments. The hollow (PSS/PAH)s capsules 
with an outermost PAH layer were suspended in a 10 pM solution of FITC-dextran of 
MW 4300 for 2 h to enable uniform distribution of the dyed polymer throughout the 
interior of the capsules and surrounding solution. This step was followed by the addition 
of lipid vesicles to form the outermost layer on the polyelectrolyte capsules. The capsules 
were then rinsed with FITC-dextran solution in order to remove any unabsorbed 
liposomes from the mixture. The final sample for FRAP experiments was a suspension of 
capsules coated with a lipid layer in a solution of FITC-dextran. Single capsules were 
isolated under a Leica confocal laser scanning microscope, photobleached, and the 
fluorescence recovery after photobleaching was monitored [97].
The diffusion in the individual capsules was studied by using a molecular 
diffusion model based on fluorescence recovery developed by Axelrod and co-workers 
[6 8 , 69] as described in Chapter 2.
4.3 Results and Discussion
4.3.1 Quartz Crystal Microbalance 
Study of Lipid- 
Polyelectrolyte Multilayers
Table 4.1 summarizes the results of polyelectrolyte-lipid LbL coatings on QCM 
resonators. The total thickness of the assembled films was less than 50 nm, indicating that 
the Sauerbrey Equation is valid [98].
Available data [3, 90-96], indicate that the prepared films consist of lipid bilayers 
sandwiched between two polycation layers. Deposition of multiple bilayers of a 
surfactant alternated with polyvinyl sulfate by the LbL method was previously reported
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[90]. The mean thicknesses for three consecutive (lipid bilayer / polyelectrolyte) layers 
for different compositions are shown in Table 4.1. The thickness of a lipid 
bilayer/polycation layer is in the range of 2-7 nm.
In most cases, assembly is stable when the concentration of a charged lipid in the 
mixtures is 20%. The obtained (lipid bilayer/poly electrolyte) bilayer thickness is in good 
agreement with the reported values for DPPC bilayer[3, 91-96, 99, 100], The total 
thickness of a DPPC bilayer is 4.6 - 5.0 nm (including a 3.4 - 3.7 nm hydrophobic layer) 
in gel state and 3.7 -  4.5 nm (2.6-3.0 nm for hydrophobic layer) in fluid state.
Table 4.1. Thickness of lipid/polyelectrolyte bilayers.
Bilayer composition8 Freq. shift / Hz
Thickness'/
nm
DPPA-DPPC 5%(w/w)/PEI 166 ± 51 2.65 ± 0.82
DPPA-DPPC 10%(w/w)/PEI 133 ± 47 2 . 1 2 ± 0.75
DPPA-DPPC 17%(w/w)/PEI 409 ± 23 6.54 ± 0.37
DPPA-DPPC 20%(w/w)/PEI 284 ± 27 4.55 ± 0.43
DPPA-DPPC 5%(w/w)/PAH 366 ± 39 5.86 ± 0.62
DPPA-DPPC 10%(w/w)/PAH 190 ± 40 3.05 ± 0.64
DPPA-DPPC 17%(w/w)/PAH 199 ± 39 3.18 ± 0.62
DPPA-DPPC 20%(w/w)/PAH 161 ± 18 2.58 ± 0.29
DPPA-DPPC 5%(w/w)/PDDA 1 1 1 ± 1 0 1.78 ± 0.16
DPPA-DPPC 10%(w/w)/PDDA 491 ± 1 0 7.85 ± 1.62
DPPA-DPPC 17%(w/w)/PDD A 327 ± 1 0 5.23 ± 1.60
DPPA-DPPC 20%(w/w)/PDDA 273 ± 42 4.37 ± 0.67
PG-PC 10%(w/w)/Chitosan 339 ± 65 5.42 ± 1.05
PG-PC 20%(w/w)/Chitosan 307 ± 25 4.91 ± 0.38
a The percentages indicate total weight percent of charged lipid components in a mixture. 
b The average of two independent experiments.
c The frequency shift of the QCM resonators was converted into thickness using the experimental equation 
A d (nm) = -0.016 AF (Hz). _____________________
Admixture of another lipid (surfactant, hydrocarbon etc.) into a lipid bilayer can 
dramatically change mean transition temperature of the mixture [1 0 1 , 1 0 2 ], and therefore,
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influence lipid bilayer thickness. In addition, oppositely charged substances can be 
incorporated between lipid heads into hydrophilic layers slightly increasing their 
thickness and decreasing hydrophobic thickness, the effect more pronounced for the 
mixtures with charged lipids [103]. However, in the case of the mixtures with low 
concentration of charged lipid (5-10% w/w DPP A), formation of incomplete lipid bilayer 
(or polyelectrolyte layer on the top of lipid bilayer) because of absence of electrostatic 
charge is possible. In the case of strong polycation PDDA, the formation of thicker layers 
can be explained by deposition of more than one DPPC-DPPS bilayer on the top of the 
polycation layer to compensate its high positive charge.
The assembly of PG-PC vesicles in alternation with cationic chitosan shows a
bilayer thickness of ~5 nm. The last architecture is of considerable importance since
chitosan is a non-toxic, natural, biocompatible polymer with antimicrobial properties,
which makes this architecture suitable for in vivo applications [104].
4.3.2 Analysis of C-Potential 
Measurements
For microparticles and microcapsule coatings we chose conditions giving a stable 
assembly and providing a 4-5 nm thick bilayer, which is consistent with the length of two 
lipid molecules [3, 90-96, 99, 105]. The lipid mixtures with 20% w/w charged lipid were 
used hereafter. Lipid layers in alternation with polyelectrolytes were assembled on 3 pm 
polymethacrylate microspheres (PMA) precoated with two PAH/PSS bilayers, and 
changes in surface charge (^-potential) of the microparticles were measured after each 
adsorption step. The detailed procedure can be found elsewhere [106]. The latex particles 
were used in this series of experiments to avoid interference of lipids with multivalent 
ions, which can precipitate lipids [107], The ^-potential values (Figure 4.1) show
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complete charge reversal with synthetic polyelectrolytes such as PDDA, PEI, and PAH, 
and the assembly with PAH shows most consistant alternation of surface charge. For 
assembly of chitosan and PG-PC, a shift in the magnitude of the positive charge was 
found, but not complete charge reversal, probably because of perturbation of lipid 
bilayers by chitosan [108].
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Figure 4.1. ^-Potential analysis of polyelectrolyte/lipid assemblies 
on PMA/(PAH/PS S)2 microparticles, the first layer corresponding 
to respective polycation (Top): lipid -  DPPA-DPPC 20% w/w with 
polyelectrolytes. (Bottom): lipid -  PG-PC 20% w/w with 
polyelectrolytes.
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4.3.3 Diffusion Properties of Lipid Coated 
Hollow Polvelectrolvte 
Microcapsules
The possibility of capsule coating with lipid bilayers was confirmed by deposition 
of a DPPC-17% w/w DPPA mixture with 3% admixture of l,2-dioleoyl-sn-glycero-3- 
phosphoethanolamine-N-(carboxyfluorescein) on the top of the hollow capsules (Figure 
4.2).
Figure 4.2. Lipid coating on (PAH/PSS)s to show lipid coating on 
microcapsules.
The FRAP model used to study the fluorescence recovery is described in Section
2.6.3 where the two-dimensional model discussed has been used in these experiments. 
Although, a three-dimensional model is recommended for volume diffusion, for diffusion 
through a thin membrane, such as the microcapsule wall in our experiments a two- 
dimensional model is a reasonable and sufficient. In the FRAP model under investigation, 
the diffusion of FITC-Dextran from the bulk to the interior of the capsule causes an 
increase in fluorescence intensity in the capsule interior. The fluorescence intensity is 
normalized over a given area in the interior of the capsule designated as region of interest 
(ROI in Figure 2.10). The fluorescence recovery after photobleaching is in the interior of
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the hollow (PAH/PSS) 5  capsules with and without lipid coating is presented in Figure 
4.3.
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Figure 4.3. Fluorescence recovery of (PSS/PAH) 5  capsules coated 
with different lipid mixtures: (1) uncoated, (2) PG-PC 20% coated,
(3) DPPA-DPPC 20% coated. The intensities of capsule interior 
are shown relatively that of surrounding solution.
As anticipated, the results indicate slower fluorescence recovery for lipid coated 
capsules than for uncoated ones (Figure 4.3). Images in the process of photobleaching are 
presented in Figure 4.4, where (Figure 4.4 A) represents the control which is uncoated 
(PAH/PSS) 5  capsule, where progressively the fluorescence intensity in the interior of the 
capsule increases over a period of 16 minutes. However in the lipid-coated capsules 
(Figure 4.4 A and B) there is no increase in fluorescence intensity even after 75 minutes.
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Figure 4.4. Fluorescence recovery after photobleaching for 
different capsules in a 10 pM solution of FITC-dextran of MW 
4300: a) an uncoated (PSS/PAH) 5  capsule, b) a capsule coated 
with one bilayer o f PG-PC ( 2 0  % w/w) and c) a capsule coated 
with one bilayer of DPP A- DPPC (20% w/w).
The diffusion properties are a representation of about 70% of the population. 
FITC fluorescence recovery in lipid-coated capsules was slower than that in uncoated 
ones indicating that the deposited lipid bilayer reduced the diffusion coefficient through 
the polyelectrolyte walls drastically for low molecular substances. The diffusion 
coefficient of FITC-dextran of MW 4300 into polyelectrolyte microcapsules was 
evaluated on the basis of a fluorescence recovery model proposed by Axelrod and co­
workers [6 8 ], For uncoated (PSS/PAH) 5 capsules, the coefficient is (7.1±2.1)xl0' 12 cm2/s. 
For lipid coated capsules it is (1.4±0.3)xl0' 13 cm2/s (DPPA/DPPC-coated), and 
(1.5±0.4)xl013 cm2/s (PG-PC-coated). These results indicate nearly two orders of
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magnitude difference in the diffusion coefficient for FITC-dextran of MW 4300 between 
lipid-coated and uncoated microcapsules.
The diffusion coefficients for FITC-dextran with a MW 4300 estimated from this 
study into uncoated and lipid coated capsules are higher than those compared with 
previously reported data [2, 3, 97]. It is possible that the different core type used for 
capsule preparation in this study is the cause of the higher diffusion coefficient. Previous 
studies on lipid-modified capsules were based on melamine formaldehyde microparticles 
and blood cells as soluble cores; however, recent evidence indicates incomplete 
dissolution of such cores, which could lead to residue in the capsules and polyelectrolyte 
capsule swelling [109]. Various diffusion models used for evaluation of diffusion 
coefficients can also introduce variability into results.
4.4 Conclusions
In summary, the multilayer architecture of lipid/polyelectrolyte capsules has been 
reported. The lipid coating introduced directly on polyelectrolyte microcapsule surface 
significantly reduces the permeability of the capsule walls. The size, wall composition, 
and diffusion properties of the microcapsules are closer to biological cell wall structure 
than many other model systems. These lipid/polyelectrolyte microcapsules can be a 
further development of traditional liposome delivery system technologies.
In the previous two chapters we have discussed the use of LbL assembly for 
diffusion control properties that can be applied to delivery of hydrophilic drugs. In the 
next chapter we will demonstrate an alternate method for delivery of hydrophobic drugs, 
through entrapment of phospholipids in mineral CaCOi microparticles
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CHAPTER 5
COMPOSITE PHOSPHOLIPID - CALCIUM 
CARBONATE MICROPARTICLES: 
CO-ENTRAPMENT OF ANIONIC 
PHOSPHOLIPIDS AND 
HYDROPHOBIC 
MOLECULES
5.1 Introduction
Calcium is the most abundant mineral in the human body. It is a component of 
bones and teeth and is also required for blood clotting, transmission of signals in nerve 
cells, and muscle contraction. The importance of calcium for preventing osteoporosis is 
probably its most well-known role. Most calcium supplements contain calcium carbonate, 
which is also one of the principal components of many biomineralization schemes 
occurring in nature, primarily involving a hierarchical organization of proteins and 
calcium salts [110]. The control of crystal morphologies of calcium carbonate is 
important for biomineralization reactions. The effect of various organic additives and 
template mediated reactions on calcium carbonate crystal morphologies has been studied 
[111-117]. Biomineralization in phosphatidylcholine vesicles by a diffusion-mediated 
process has been reported as a model system for biomineralization [1 1 1 , 118].
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Most of the research has been centered on elucidating particle formation and 
understanding the kinetics and mechanisms of crystallization [119-124], Recently, 
Sukhrukov et al. [53] showed that porous calcium carbonate microparticles can be 
synthesized by directly mixing Ca and CO3 ' salts, which can be used as a template for 
polyelectrolyte LbL assembly. Here we report the synthesis of calcium carbonate 
microparticles of a highly porous nature, having phospholipid molecules entrapped in the 
porous structure, resulting in an organic/inorganic complex matrix. The microparticles 
can be used to load hydrophobic molecules in an inorganic core with potential 
applications in medicine and industry. The calcium carbonate microparticles synthesized 
in this work also show a prospect for air based nasal drug delivery systems. A surface- 
mediated reaction for the preparation of the mesoporous calcium carbonate microparticles 
is proposed. The resulting microparticles have phospholipids entrapped in the mineral 
matrix of CaCCh with the hydrophobic material localized in the hydrophobic regions of 
the phospholipids vesicles (Figure 5.1). Moreover, this scheme can be extended to the 
entrapment of surface active macromolecules, including proteins, and peptide drugs.
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Drugs:
H ydrophobic  m o lecu le s  
-»  e n tra p e d  in th e  
h y d ro p h o b ic  reg io n  of 
th e  p h s o sp h o lip id s
Nifidapine,
Dexamethasone
CaC03 microparticles 
with phospholipids 
entraped in matrix
Fluorescent Sensoric elements: 
Ru(dpp) ( Oxygen sensitive dye) 
fluorescent microparticles
Figure 5.1. Scheme for entrapment of hydrophobic drugs in 
mineral matrix. The hydrophobic molecules are localized in the 
hydrophobic tail regions of the phospholipids molecules. The 
hydrophilic head interacts with the mineral matrix.
These microparticles are amenable to LbL assembly for surface modification to 
make the surface of the microparticles biocompatible; the particles can also be used as 
templates for preparing hollow polyelectrolyte microcapsules by various approaches 
[125]. The presence of phospholipids in the calcium carbonate matrix also facilitates 
entrapment of small hydrophobic molecules in conjugation with other bioactive 
molecules.
5.2.1 Materials.
The lipids— l,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA), 1,2-distearoyl-sn-glycero- 
3[phospho-rac-(l-glycerol)])(sodium salt) (DSPG), l,2-dipalmitoyl-sn-glycero-3- 
phosphatidylcholine (DPPC) and l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- 
(carboxyfluorescein) (FITC-EA) were purchased from Avanti Polar Lipids. Calcium 
Chloride (CaCb), and ammonium bicarbonate (NH4 HCO3 ) were purchased from Sigma
5.2 Experimental
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and Fluka respectively. Tris(4,7-diphenyl-l,10-phenanthroline)ruthenium(II) dichloride 
complex ([Ru (dpp^JCb) was purchased from Fluka.
5.2.2 Preparation of Calcium 
Carbonate Particles 
Incorporating Phospholipids 
in the Matrix
To prepare calcium carbonate microparticles incorporating phospholipids in the 
matrix, liposomes of DPPA (l,2-dipalmitoyl-sn-glycero-3-phosphate), DSPG (1,2- 
distearoyl-sn-glycero-3[phospho-rac-(l-glycerol)])(sodium salt), and DPPA 20% (w/w)- 
DPPC (1, 2- dipalmitoyl -sn-glycero-3-phosphocholine) mixtures were prepared in DI 
water using standard protocol described in the previous chapter. Two mL of 1 mg/mL 
phospholipid liposomes were first treated with (0.01 to 0.15 M) Ca2+ ions (CaCk) for 10 
minutes with slow stirring to form cochleates [126, 127]. The cochleates were dispersed 
by sonication followed by immediate addition of 0.375 M NH4HCO3 with different 
volume ratios and in large excess of the stochiometric reaction requirement. After 15 
minutes of reaction, the products were centrifuged and rinsed in DI water three times 
followed by rinsing in a 1 : 1  methanokchloroform mixture three times to remove any free 
ions and phospholipids. The samples were then dried under a stream of nitrogen.
5.2.3 Preparation of Calcium 
Carbonate Microparticles 
Without Phospholipids in the 
Matrix
Pure calcium carbonate microparticles were prepared by mixing equal volumes of 
CaCb and NH4HCO3 in a constant volume reactor, at ambient conditions, with uniform 
stirring. Following a 15 minute reaction, the reaction products were centrifuged, rinsed in 
deionized water (DI water), and dried under a stream of dry nitrogen.
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5.2.4 Preparation of Calcium 
Carbonate Microparticles 
with Hydrophobic Molecule 
Entrapped in the Matirix
During the preparation of liposomes, as indicated in Section 5.2.1, the 
hydrophobic molecule or fluorescent phospholipid is added to the chloroform mixture 
during cake formation and the liposomes consequently formed incorporate the 
hydrophobic molecules in their fatty side chains. The rest of the procedure remains the 
same.
5.3 Results and Discussion
5.3.1 Characterization of 
Morphology and 
Microstructure
To study the morphology and microstructure of the CaCC>3 microparticles, the 
samples obtained were visualized using Scanning Electron Microscopy (SEM, Gemini, 
Leo 1550). The crystal structure of the CaCC>3 microparticles synthesized in the presence 
and absence of anionic phospholipids were also characterized using X-ray diffraction
• 7+ 3(Philips Cu xa radiation). In the absence of any additives, the reaction of Ca and HCO " 
yields particles with diameters in the range of 10±5 pm. The SEM images in Figure 
5.2(a) and the powder X-ray diffraction pattern in Figure 5.3 indicates calcite polymorph 
as the predominant form
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Figure 5.2. Representative SEM images of calcite microcrystals 
prepared by reaction of 1 mL 0.01 M CaC12 + 1 mL 0.375M 
NH4HC03 + 2 mL of DI water (a). Porous CaC03 microparticles 
by first reacting 2 mL of 1 mg/mL DPPA +1 mL 0.01 M CaC12 +
(after 10 min) 1 mL of NH4HC03 (b), these microparticles contain 
3%(w/w) phospholipids in matrix.
The shape of the calcite crystals depends on the rate of mixing of lipids during 
reaction. No-stirring results in wide size distributions of particles with fewer crystal 
faces, whereas vigorous stirring yields narrower size distributions with multifaceted 
particles (Figure 5.2(a)). Under identical conditions used for preparation of calcite 
microparticles described above, the presence of phospholipids in the reaction-mixture 
results in particles that are porous in nature and have no crystalline edges Figure 5.2(b). 
The size distributions of these microparticles are in a range of 5±2 pm.
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The powder X-ray diffraction pattern of calcium carbonate microparticles 
synthesized in the presence and absence of DPPA was used to determine the polymorphs 
present in the synthesized mixture. The X-ray diffraction patterns indicate that in the 
absence of phospholipids the resulting calcium carbonate microparticles are 
predominantly calcite (Figure 5.3 (top)). In the presence of DPPA the resulting 
microparticles are predominantly veterite polymorph (Figure 5.3). It is well known that 
the veterite polymorph is thermodynamically less stable than calcite. The occurrence of 
less stable veterite polymorph in the presence of DPPA, strongly suggests to the 
involvement of phospholipids surface in altering the nucleation and crystallization of 
CaCC>3 . However, traces of calcite peaks are also seen (less than 2% by volume), which 
can be attributed to the phase transformation of the microparticles or some nucleation 
occurring in aqueous phase as opposed to phospholipid surface.
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Figure 5.3. X-ray diffraction pattern of calcium carbonate 
microparticles. The top graph shows the X-ray diffraction pattern 
of calcite with the principal peaks highlighted [117]. The bottom 
graph shows the X-ray diffraction pattern of calcium carbonate 
microparticles synthesized in the presence of DPPA (V-veterite, C- 
calcite).
5.3.2 Effect of Molar Ratio of 
Reactants
The size of the particles depends on the initial concentration of reactants. The 
influence of molar ratio of reactants on the mean size of microparticles gives an insight 
into this aspect. The weighted mean of the microparticles is plotted as a function of molar 
ratio of bicarbonate and calcium (Figure 5.4) indicates a nonlinear decrease with 
increasing concentration.
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Figure 5.4. Effect of the ratio of Ca2+ to HC03- ions on the size of 
calcium carbonate microparticles based on 0.375 M concentration 
of NH4 HC03 in total volume, with DPPA concentration constant 
at 0.2 mg/mL.
The mean diameter of the microparticles decreases with decreasing CaCl2 
concentration. Higher molar ratio of CaCl2, relative to phospholipids, results in a non- 
homogeneous distribution of phospholipids in the CaCC>3 matrix that occasionally results 
in rombohedral CaCC>3 calcite in the final product. This observation can also be 
correlated to the fact that with lower phospholipid concentrations or non-uniform stirring 
of the reaction mixture, nucleation may begin in the aqueous phase as opposed to on the 
phospholipid surface and yield a mixture of porous CaCC>3 microparticles as well as 
calcite crystals.
The results indicate that a higher concentration of phospholipids to Ca2+ results in 
a narrow size distribution of the resulting microparticles. In the presence of excess 
phospholipids, most of the calcium ions are bound to the phospholipid surfaces, which
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results in fewer reaction centers in the media. The nucleation occurs on phospholipid 
surfaces or begins in solution and propagates on the phospholipid surface resulting in a 
predominantly phospholipid surface mediated reaction. To verify this hypothesis, 
5%(w/w) of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) 
(FITC-EA) was admixed with DPPA and used to prepare the microparticles. The 
resulting microparticles were visualized using a confocal laser scanning microscope 
(CLSM, DMI-RE2). Figure 5.5(a) shows the confocal microscopy image of calcium 
carbonate microparticles prepared in the presence of phospholipids admixed with FITC- 
EA, which fluoresces green, and Figure 5.5(b) shows calcium carbonate microparticles 
entrapped with [Ru(dpp)3 ]2+ which fluoresces red; it will be discussed in Section 5.3.5. 
The distribution of fluorescence was uniform in the calcium carbonate matrices prepared 
in the presence of excess phospholipids (Figure 5.5(a)) compared with microparticles 
prepared in a phospholipid deficient reaction mixture (Figure 5.5(a) (inset)). The images 
also illustrate that the distribution of phospholipids in the matrix is uniform and lends 
support to the postulated phospholipid surface mediated reaction of calcium and 
carbonate ions.
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Figure 5.5. CLSM image of cross-section of (a) calcium carbonate 
microparticles incorporating FITC-EA; in phospholipid deficient 
medium the non-uniform distribution of phospholipids in the 
matrix is observed (inset) and (b) prepared by reaction of CaC12 
and NH4HC03 in the presence of (DPPA 20%(w/w) -DPPC 
mixture containing [Ru(dpp)3]2+ which is a hydrophobic molecule 
localized in the hydrophobic region of fatty acid side chain.
5.3.3 Thermogravimetric Analysis 
of Calcium Carbonate 
Microparticles Prepared by 
Different Methods
Thermogravimetric analysis of calcium carbonate microparticles was used to 
determine the temperature at which different volatile species desorb from a sample. 
Figure 5.6 shows the changes in weight with temperature, the temperature of the sample 
crucible was increased at the rate of 5°C per minute. The x-axis shows the changes 
temperature and the y-axis is the normalized weight of the sample.
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Figure 5.6. Thermogravimetric analysis of (A) calcite and DPPA 
and (B) calcium carbonate microparticles prepared in the presence 
of DPPA, the change in weight is shown as percentage total weight 
(inset) (1) and mixture of calcite and DPPA (2). The temperature 
was increased at 5°C/minute.
Thermogravimetric analysis of the calcium carbonate microparticles prepared in 
the presence of DPPA indicated that the DPPA in the calcium carbonate matrix desorbed 
at higher temperatures (385±6 °C), compared with either pure DPPA (337±6 °C) or a 
physical mixture of phospholipid with calcite microparticles (326±6 °C) (Figure 5.6). The 
desorption of carbon dioxide from calcium carbonate also occurs at higher temperature 
(706±6 °C) compared with pure calcite (654±6 °C) or a physical mixture of calcite and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
102
DPPA (681±6 °C). The higher temperature of desorption can be attributed to a strong
calcium carbonate phospholipid interaction. The microparticles contain ~ 2.5-5 % by wt.
of phospholipids in the matrix. Ca2+ ions interact with anionic phospholipids
(phosphatidic acid, phosphatidyl serine) to form a co-ordinate complex such that each
Ca2+ ion demonstrates four, and in some cases six, coordination valencies that bonds with
phosphate groups of phosphilipids or with other molecules like water [126, 127].
Lamellar amphiphile-calciumhydroxyapatite structures have been extensively studied,
which also suggest existence of such calcium ion-phospholipid coordination[65, 66,128],
The results strongly suggest that this theory could be extended to the carbonated calcium
ions in our system. Another contributing factor to the delayed desorption could be the
strong Van der Waals and hydrophobic interactions between the phospholipid vesicles
and the mesoporous matrix of the calcium carbonate. The negative-charged phospholipid
vesicle structure prevents HCO ' ion penetration into the interior of the vesicle, thus
limiting the calcification occurring only on the surface of that structure; this could lead to
nanometer sized voids explaining the porous nature of the calcium carbonate
microparticles synthesized.
5.3.4 Long-Term Stability of the 
Calcium Carbonate 
Microparticles
The stability of porous calcium carbonate microparticles in DI water was studied 
using particles incorporating phospholipids (FITC-EA, DPPA, and DPPC mixture) with 
confocal microscopy (Leica DMI RE2). Over a period of one to three weeks, the veterite 
microparticles recrystallized to calcite. The first signs of recrystallization were observed 
after one week of storage in an aqueous solution and progressed for 3-4 weeks, after 
which nearly 90% of the microparticles had recrystallized and the phospholipids were
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excluded from the matrix. However, when the particles are dried after preparation using a 
methanol:chloroform mixture, the particle morphology remains unchanged over 3-4 
months.
5.3.5 Incorporation of 
Hydrophobic Molecules in 
Calcium Carbonate Matrix to 
Simulate a Model Drug
To study the possibility to incorporate hydrophobic molecules, a model 
fluorophore, tris(4,7-diphenyl-l,10-phenanthroline)ruthenium(II) dichloride complex 
([Ru(dpp)3]Cl2 ), was incorporated in the phospholipid vesicles and the resulting 
microparticles studied using CLSM (Figure 5.5(b)). [Ru(dpp)3]2+ is insoluble in DI water, 
but readily localizes in the hydrophobic region of the phospholipid bilayer. The 
distribution of the dye is uniform in the matrix of the calcium carbonate. Figure 5.5(b) 
shows that the distribution of the hydrophobic molecule [Ru(dpp)3 ]2+ is as uniform as the 
distribution of the amphiphile itself. This result is important from a pharmaceutical 
standpoint, since it demonstrates the possibility that these microparticles can be used as 
carriers for hydrophobic drug molecules. Preliminary trials showed feasibility to entrap 
the drugs nifidapine and dexamethasone in the calcium carbonate matrix. However 
further investigation is necessary to draw conclusions.
5.4 Conclusion
Anionic phospholipid (phosphatidic acid, phosphor glycerol) mediated synthesis 
of calcium carbonate microparticles from Ca2+ and HCO3' salts yields a composite 
organic/inorganic matrix. The inorganic matrix is predominantly the veterite polymorph 
of calcium carbonate. The microparticles contain ~ 2.5-5 % by wt. of phospholipids in 
the matrix. The phospholipids show stable entrapment in the calcium carbonate matrix
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with strong interactions with the matrix. Such architecture is conducive to the entrapment 
of small hydrophobic molecules and other bioactive substances in an inorganic matrix.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
In this dissertation the author has demonstrated that LbL self-assembly can be 
applied to encapsulate peptide microparticles in the presence of high concentrations of 
uncharged polymers such as PEG. Two different approaches have been used for 
entrapment, which rely on the isoelectric point of the peptide. With insulin as a model 
drug, with an isoelectric point ~5.9, formulations were prepared at pH 5.8 and at neutral 
pH 7.0. Both pH values are relevant for pharmaceutical formulations, which are typically 
prepared in the range of pH 4.0 to 8.0. Human insulin is unstable in acidic pH because of 
deamidation of the Asparagine (Asn) residue located at A21, leading to long term storage 
instability. However, acidic pH insulin formulations dissociate at a faster rate compared 
with neutral pH formulations. At pH 5.8 the insulin microparticles behave like a positive 
core and LbL assembly was achieved using a polyanion as the first layer. The LbL thin 
films form complex with the outermost layer of insulin molecules, imparting some degree 
of structural integrity to the microparticle in storage. Available literature [8] strongly 
suggests that the structural integrity prevents the release of insulin in storage at pH 5.8, 
thus limiting the adverse effects of dilution of insulin. The adverse effects which could
105
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induce loss of therapeutic value of insulin include— polymerization, chemical 
modification, adsorption to storage vessel wall, fibril growth and crystallization. At pH 
7.0 PROMAXX® insulin microparticles behave as a negative core and the LbL assembly 
was performed using a polycation as the first layer. It was observed that differential 
number of layers enables differential control of drug. This effect was most pronounced in 
ProtS/CMC combination. This is interesting from the point that the adsorbed layers are 
nanometers thick and the influence of a single outermost layer can be significant. 
However, there is significant penetration of polyelectrolyte inside the insulin core, thus 
forming stable complex in storage. This complex formation imparts similar benefits as 
stated above for pH 5.8.
The study involving complex formation established the amount of polyelectrolyte 
required for complete complex formation. This information is useful for process scaleup 
and can be efficiently employed on a larger scale to avoid the rinsing steps that were 
performed in the experiments described in this work. The absence of rinsing would 
consequently lead to a reduction in the amount of materials used, providing significant 
cost benefits. Further, this information alone can be used to create formulations with 
release properties entirely regulated by the amount of polyelectrolyte added. The 
experimental results relating different polyelectrolytes and corresponding release kinetics 
can be used as a library for polyelectrolyte-insulin complex reversibility, thus aiding 
better material selection in the future. Such a library also provides information for better 
understanding insulin-polyelectrolyte complexes and designing a mathematical model for 
a specific material, which in turn would lead to the development of an in vivo model. The 
work presented in Chapter 3 leads us to a general idea which applies to all LbL
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assemblies on protein cores, in that when a negatively charged protein interacts 
alternatively with a cationic and anionic polyelectrolyte, the relative affinity of the inter­
polyelectrolyte interaction may dictate the overall strength of protein-polyelectrolyte(s) 
complex. Converse is true for a positively charged protein core.
The insulin coating with LbL was performed mostly with the use of biologically 
derived polyelectrolytes, with occasional use of synthetic polyelectrolytes to relate with 
existing knowledge on LbL. Consequently, the experiments were designed to identify the 
polyelectrolytes which yielded the desired results, and investigate them further. It was 
demonstrated that different polyelectrolytes can be used as the outermost coating, thus 
imparting desired surface charge at any pH value. This work also suggests that the use of 
pegylated polyelectrolytes as the outermost layer of the LbL assembly on insulin 
microparticles results in a PEG-terminated outer coating, which has been known to be 
completely biocompatible.
The use of phospholipids in LbL assembly was treated as a separate chapter, 
because establishing proof of concept was essential prior to use in drug formulation. 
Phospholipids were used because they are inherently biocompatible in nature and are 
used in existing drug formulations. However, the work presented in this dissertation 
established the right concentration of charged anionic and zwitterionic lipids for use in 
LbL. Further, as an extension of work by Moya et al.[3], who demonstrated the feasibility 
to make a single lipid bilayer structure, this work presents the prospect of using 
multilayer lipid-polyelectrolyte constructs. Differing from earlier works, which enable 
the coating of solid colloidal particles, this work establishes the coating on hollow 
polyelectrolyte multilayer capsules. Moreover, the author has provided the first of its kind
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comparison of diffusion properties of hollow polyelectrolyte capsules and lipid coated 
polyelectrolyte capsules. Conventional LbL assembly does not use phospholipids as a 
component of the thin films, and relies primarily on the number of layers of 
polyelectrolyte to regulate the diffusion of substances from microcapsules. Increasing 
number of layers incurs a great deal of time and materials cost. The use of phospholipids 
could significantly reduce these, and the work presented in this dissertation is a 
significant achievement in terms of establishing the usefulness of lipid polyelectrolyte 
multilayers. The choice of FITC-Dextran MW4300 is guided by its molecular weight, 
which is close to the molecular weight of insulin. The use of a diffusion technique used to 
load hollow polyelectrolyte shells could potentially be used to load hollow 
polyelectrolyte multilayer capsules, followed by outermost lipid coating could be used to 
design a slow-release formulation. Alternatively, the use of insulin cores or crystals 
coated with LbL multilayers followed by an outermost lipid coat can also be envisaged.
The size, wall composition, and diffusion properties of the lipid/polyelectrolyte 
microcapsules developed in this work are closer to biological cell wall structure than 
many other model systems. These lipid/polyelectrolyte microcapsules can be treated as a 
further development of traditional liposome delivery system technologies. This work 
could be beneficially exploited by reinforcing liposomal technology with the use of 
electrostatic layer-by-layer technology, thus enhancing the existing liposomal technology 
for drug delivery.
Extending the particulate delivery technology the incorporation of hydrophobic 
and surface active molecules in an inorganic core is a new dimension in drug delivery. 
The novelty of the method lies in the use of anionic phospholipids (phosphatidic acid,
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phosphoglycerol)-mediated synthesis of calcium carbonate microparticles from Ca2+ and 
HCO3' salts yields a composite organic/inorganic matrix. The inorganic matrix is 
predominantly the veterite polymorph of calcium carbonate. The microparticles contain ~ 
2.5-5 % by wt of phospholipids in the matrix. The phospholipids show stable entrapment 
in the calcium carbonate matrix and strong interactions with the matrix. Such architecture 
is conducive to the entrapment of small hydrophobic molecules and other bioactive 
substances in an inorganic matrix. Surprisingly, a large number of macromolecules are 
surface active in that they show a tendency to selectively partition at an interface. The 
development of calcium carbonate microparticles entrapping phospholipids is based on 
the surface active properties of phospholipids. It can be inferred that, this technique of 
entrapping material can be extended to insulin, and similar peptide drugs which are 
amphoteric in nature. Further phospholipids can be used advantageously to boost the drug 
loading in the calcium carbonate matrix because existing literature on material loading 
into calcium carbonate microparticles suggests a loading of less than 1% in most cases.
6.2 Future work
The insulin reformulation with LbL was designed with biocompatible, 
biodegradeable polymers. The choice of materials was guided by its biological source, 
and inherent capacity of biological organisms to degrade the materials, or the presence of 
pathways for removal of the material. Although the word biocompatibility is used 
liberally to describe a whole set of biologically derived polymers, in vivo testing is 
essential in establishing the true behavior of the material for a given mammalian species. 
Further, the viability of the drug depends on its bioavailability and release kinetics in
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vivo. Hence, animal models need to be developed for nasal drug delivery of the prepared 
formulations.
As a further development the use of phospholipids in LbL scheme can be applied 
to insulin cores, which is proving a problem under the conditions used for preparation of 
LbL thin films on PROMAXX® insulin microparticles. This work used PEG buffer for 
preparation of the insulin drug formulation, the buffer also contains trace quanties of Zn 
ions, both PEG and zinc cause problems with phospholipid vesicle stability. Moreover 
the work presented in this dissertation involved the use of DI water for preparation of 
phospholipid-polyelectrolyte multilayer films adding a constraint to the use of the 
technique. An investigation on the suitability of other amphiphilic molecules may be 
required.
The calcium carbonate microparticles show good prospect for loading 
hydrophobic and surface active drugs. Testing the efficacy of the platform for drugs and a 
study of the rehology of the particles for air based delivery systems would be crucial for 
the development of the platform.
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